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Abstract 
 
 
While memory CD4 T cells are critical for effective immunity to pathogens, 
the mechanisms underlying their generation are poorly defined. Although 
extensive work has been done to examine the role of antigen (Ag) in shaping 
memory formation, most studies focus on the requirements during the first few 
days of the response known as the priming phase. Little is known about whether 
or not Ag re-encounter by effector T cells (late Ag) alters CD4 memory T cell 
formation. Since influenza infection produces a large, heterogeneous, protective 
CD4 memory T cell population, I used this model to examine the role of late Ag in 
promoting CD4 memory T cell formation. 
In the experiments presented in this thesis, I demonstrate that late Ag is 
required to rescue responding CD4 T cells from default apoptosis and to program 
the transition to long-lived memory. Responding cells that failed to re-encounter 
Ag had decreased memory marker expression and failed to produce multiple 
cytokines upon re-stimulation. Ag recognition is required at a defined stage, as 
short-term Ag presentation provided 6 days after infection is able to restore 
canonical memory formation even in the absence of viral infection. Finally, I find 
that memory CD4 T cell formation following cold-adapted influenza vaccination is 
boosted when Ag is administered at this stage. These findings imply that 
persistence of viral Ag presentation into the effector phase is the key factor that 
determines the efficiency of memory generation. They also suggest that 
administering Ag during the effector stage may improve vaccine efficacy.
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CHAPTER I: Introduction 
 
 
Overview 
 The mechanisms that govern the selection of a few of the many Ag-specific 
effector CD4 T cells present at the peak of the response to form memory are largely 
unclear. While many studies have suggested that memory fate determination 
occurs early in the response, others have demonstrated that signals received at 
later stages can alter memory T cell formation. Recent work from our lab has 
identified a checkpoint that occurs during the effector phase of the response during 
which autocrine IL-2 signals are required for CD4 memory T cell formation (1). 
Since a dominant driver of IL-2 production by CD4 T cells is cognate Ag 
recognition, I sought to test if Ag recognition at this checkpoint was required to 
induce IL-2 production and promote memory formation. 
The aim of my thesis work was to understand what role Ag presentation 
during the effector stage of the response plays in shaping CD4 memory T cell 
formation. To this end, I used a mouse-adapted influenza infection model that is 
known to induce potent CD4 memory T cell generation (2–4). Not only is a long-
lived heterogeneous memory CD4 T cell population formed following influenza 
infection, it is capable of mediating heterosubtypic protection (3, 5). While studying 
CD4 memory T cell formation in this model provides valuable insights to a basic 
mechanism of memory generation, it also has translational relevance. Given that 
memory CD4 T cells enhance antibody (Ab) responses (6, 7), CD8 T cell 
responses (8–11), innate responses (12), as well as mediate direct effector activity 
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(2, 4, 13, 14), understanding the requirements for their generation is critical to 
rational vaccine design. T cell responses are largely directed against highly 
conserved epitopes, this suggests that a vaccine that effectively enhances T cell 
memory might lead to a more broadly protective vaccine (15). In fact, many 
vaccination efforts are underway that focus on enhancing memory T cell formation 
(15). This thesis may help guide those efforts by establishing the Ag requirements 
for effective memory generation.  
 The following introduction will provide background on the influenza virus 
and its pathogenesis. Understanding its mode of infection provides insight into Ag 
presentation and the effectiveness of vaccination strategies. I will discuss T cell 
responses to influenza infection to orient readers to the specifics of viral and T cell 
kinetics as well as the phenotype and subset differentiation of T cells during 
influenza infection. I will then focus on T cell responses in general and introduce a 
few key molecules that arise in my thesis and discuss their relevance to contraction 
and memory T cell formation. I will end with a discussion of the role of Ag in shaping 
both effector and memory T cell responses. Overall this introduction will explain 
the relevant work in the field and illuminate the contributions presented in this 
thesis. It will also put the work into the greater context of how it may ultimately aid 
translational efforts in influenza vaccination. 
 
Influenza viruses 
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A. Influenza Viruses: An overview 
 Influenza viruses are part of the family Orthomyxoviridae. Influenza B and 
C viruses predominantly infect humans, while Influenza A viruses (IAV) infect a 
wide range of mammals and birds (16). Influenza C viruses are endemic and cause 
mild respiratory disease, while Influenza A and B are responsible for seasonal 
epidemics (17). Since Influenza A virus (IAV) can infect many different animals, 
gene segment rearrangement can occur resulting in novel strains which are 
responsible for pandemic outbreaks (16, 18). IAV are classified based on their 
hemagglutinin (HA) and neuraminidase (NA) subtypes with HA having 18 subtypes 
and NA having 11 subtypes (19–21). IAV HA phylogeny can be further classified 
into group 1 (H1,H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18) or group 
2 (H3, H4, H7, H10, H14, and H15) (22). The World Health Organization guidelines 
for influenza nomenclature are Type (A, B, C) / host (if non-human) / place of 
isolation / isolation number / year of isolation (17).  
 
B. Influenza Viruses: Structure and Genome 
Influenza viruses are enveloped, negative-sense, single-stranded RNA 
viruses containing seven (Influenza C) or eight (Influenza A and Influenza B) gene 
segments. The eight gene segments in Influenza A and Influenza B viruses are 
PB1, PB2, PA, HA, NP, NA, M, and NS (Figure 1.1). Polymerase basic 1 and 2 
(PB1 and PB2) and Polymerase acidic (PA) encode proteins that together form a 
viral RNA-dependent RNA polymerase complex (23). Influenza C viruses have a  
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Figure 1.1 Influenza Virus Structure and Genome   
A 
B  
vRNP 
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Figure 1.1. Influenza Virus Structure and Genome 
 
(A) Influenza A virus (IAV) structure. IAV is an enveloped, negative-sense, single-
stranded RNA virus. The viral envelope consists of a host cell-derived lipid bilayer 
along with viral hemagglutinin (HA) and neuraminidase (NA). The ion channel 
matrix (M2) is a transmembrane protein with a small, highly conserved ectodomain 
exposed at the viral surface. The inner surface envelope matrix 1 (M1) protein 
forms a protein layer under the lipid bilayer. The genome consists of eight gene 
segments including Polymerase basic 1 (PB1), Polymerase basic 2 (PB2), 
Polymerase acidic (PA), HA, nucleoprotein (NP), NA, matrix (M), and non-
structural (NS). (B) Viral gene segments are coated with many NP proteins and 
one RNA polymerase complex composed of PB1, PB2, and PA per gene segment. 
This structure is termed viral ribonucleoprotein (vRNP).  
Figure adapted from: Sridhar, S., K. Brokstad, and R. Cox. 2015. Influenza 
Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza 
Vaccines. Vaccines 3: 373–389. Creative Commons Attribution license. 
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subunit called polymerase 3 (P3) instead of PA (23). HA encodes hemagglutinin 
that forms a trimeric glycoprotein present in the viral envelope. HA binds sialic acid 
on the surface of host cells to mediate cell entry (24). NP encodes the 
nucleoprotein that encapsulates all gene segments in the virion and is essential 
for viral replication and transcription. NA encodes neuraminidase which is a 
tetrameric glycoprotein in the viral envelope that mediates the exit of newly formed 
virions from the host cell by cleaving sialic acid linkages (25). M encodes the inner 
surface envelope matrix 1 (M1) protein which forms a protein layer under the host 
cell-derived lipid bilayer. M also encodes the ion channel matrix (M2) that is 
present in the viral membrane. NS encodes the non-structural protein (NS1) which 
is an antagonist of Type I IFN (26). Through alternative splicing, NS also encodes 
nuclear export protein (NEP, also known as NS2) which mediates the export of 
viral ribonucleoprotein (vRNP) complexes from the nucleus to the cytoplasm (17, 
20, 27–29).  
 The viral envelope consists of a host cell-derived lipid bilayer which 
contains cholesterol rich lipid rafts (28, 30). The envelope contains the viral 
proteins HA, NA, and M2. HA is by far the most abundant protein, making up about 
80%, NA makes up about 17%, and M2 is only present at about 16 to 20 molecules 
per virion (29). Virions are pleiomorphic but are generally spheroid in shape and 
are around 100nm in diameter (31). Under this lipid bilayer is a protein layer that 
consists of M1 and small amounts of NEP. The viral core consists of helical vRNPs 
which are composed of gene segments encapsulated with many NP molecules 
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and associated with one viral RNA polymerase complex per gene segment (Figure 
1.1). 
 
C. Influenza Viruses: Viral entry 
 HA binds to sialic acid (SA) bound to the terminal end of glycoproteins found 
on host cell surfaces. HA molecules have varying affinities for different SA 
linkages. IAVs that have evolved to infect epithelial cells of the human respiratory 
tract have HA molecules with a high affinity for a2-6 SA, while those that have 
evolved to infect birds have a high affinity for a2-3 SA which is the most abundant 
linkage present in avian gut epithelial cells. a2-3 SA linkages are also present at a 
low frequency in the human lower respiratory tract which is why humans can be 
infected with avian-evolved IAV (32). Interestingly, swine tracheal epithelial cells 
have both SA linkages and are therefore thought to provide an important source 
of pandemic strain formation as a result of co-infection.  
 Prior to activation, the HA precursor (HA0) must be cleaved into the HA1 
and HA2 subunits. This requires a host cell serine protease. For human IAV, HA0 
contains a monobasic cleavage site that can only be cleaved by a few trypsin-like 
proteases thought to be primarily present in the lung epithelia. Cleavage can be 
mediated by secreted proteases or transmembrane proteases which may cleave 
the HA0 prior to viral budding (33–35). It is therefore possible for local cells lacking 
the required enzyme to become infected by virions coated with pre-cleaved HA but 
these cells are unlikely to propagate the virus due to their inability to cleave HA. 
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For highly pathogenic H5 and H7 strains, the HA0 contains a multibasic cleavage 
site which can be cleaved by the more ubiquitous furin-like proteases allowing 
productive infection of a broader range of cell types (35).  
The HA1 subunit contains the sialic acid binding domain. The HA2 subunit 
contains the fusion peptide. Cleavage is necessary for viral fusion because it 
mediates a conformational change in HA that releases the fusion peptide from the 
C-terminus of HA1, preparing it to function at low pH (35). Once HA binds sialic 
acid on the host cell surface, receptor-mediated endocytosis occurs and the virus 
enters an endosome within the cell cytoplasm. As the pH in the endosome 
becomes more acidic (pH 5-6), HA undergoes a conformational change exposing 
the fusion peptide. The fusion peptide is then inserted into the host cell membrane 
and through further conformational changes the viral and host membranes are 
brought in close proximity to each other and form a stalk that eventually collapses 
forming a pore. This process likely requires multiple HA interactions with SA on the 
cell surface. Low pH also allows vRNPs to dissociate from M1 via the M2 ion 
channel. Once the pore is formed the vRNPs are released into the host cell cytosol 
(24, 28, 36). 
 
D. Influenza Viruses: Transcription and Replication 
Unlike many RNA viruses, influenza viral replication occurs in the nucleus 
instead of the cytoplasm. Once the vRNPs are in the nucleus both transcription 
(the generation of mRNA for translation into viral protein products) and replication 
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(the generation of more negative-sense RNA for packaging into new virions) are 
carried out. Viral transcription of the negative-sense RNA is executed by the viral 
RNA polymerase complex associated with each vRNP. The PA and PB2 subunits 
cleave 5’ caps from host mRNA (termed “cap-snatching”), these serve as primers 
to initiate transcription. The PA C-terminal domain moves single-stranded RNA 
into the active site located on the “large domain” of the polymerase that consists 
of PB1 and PB2. Transcription is terminated with polyadenylation (Poly-A). 
Resulting mRNAs are then transported to the cytosol where they are transcribed 
into protein by host cell machinery (37, 38). Viral replication requires the generation 
of intermediate positive-sense complimentary RNPs (cRNP) that lack 5’ Caps and 
Poly-A tails. These cRNP then serve as efficient templates for the synthesis of 
many negative-sense RNPs that can be packaged into new virions. Translation of 
mRNA into more viral NP and viral RNA polymerase is required for replication to 
take place. (23, 37, 39).  
 
E. Influenza Viruses: Viral Budding 
 Viral budding is a complex process that is initiated by targeting of HA and 
NA to lipid rafts on the host cell surface. M1 then binds the cytoplasmic tails of HA 
and NA and forms a docking site for vRNPs. This is followed by recruitment of M2 
which is responsible for facilitating the curvature of the cell membrane at the 
budding site which leads to membrane scission and virion release (29, 40, 41). NA 
plays a critical role in this process in cleaving SA moieties to prevent HA binding 
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to the host cell membrane or causing aggregation with other new virions (20, 25). 
 
F. Influenza Viruses: Disease 
 Although influenza viral infections are generally self-limiting, they cause 
significant morbidity and mortality in the young, elderly, and immune-compromised 
(17, 22, 27). Seasonal influenza related deaths vary drastically from year to year, 
ranging from around 3,000-49,000 deaths in the United States per year (42). 
Pandemic influenza strains can be much more catastrophic, with the most extreme 
example being the 1918 Spanish Influenza pandemic which resulted in around 50 
million deaths worldwide (16). Fatal complications following influenza infection 
include pneumonia and secondary bacterial infections (16, 17). In fact, most of the 
deaths seen in the 1918 Spanish flu pandemic as well as those seen in seasonal 
epidemics were associated with a secondary bacterial infection (17). Additionally, 
mutations in viral genes can lead to increased virulence, most notably a mutation 
found in the HA0 cleavage site of H5 and H7 broadens the host protease 
requirements enabling the virus to infect cells other than bronchial epithelium (16, 
17). Therefore, influenza poses a significant health risk that warrants further 
examination of how effective vaccination can be achieved. 
 
Influenza vaccination 
 
A. Influenza vaccination: Challenges 
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 IAV is an extremely agile virus, rapidly acquiring mutations to respond to 
strong selection pressure by neutralizing HA-specific Ab as well as anti-viral drugs 
including those targeted against NA. These mutations are rapidly acquired due to 
the lack of proofreading function of the influenza RNA polymerase resulting in a 
mutation rate of about 1-8 X 10 3 substitutions per site per year (16). Mutations 
acquired in the HA or NA glycoproteins is termed “antigenic drift”. Additionally, 
“antigenic shift” occurs when a host is co-infected with two or more different 
influenza strains resulting in gene reassortment that includes the HA and NA 
genes. Wild aquatic birds are thought to be the dominant hosts in which this occurs, 
as IAV generally results in asymptomatic gastrointestinal infections and mixed co-
infections are quite common (43). Since most vaccine-induced immune responses 
target the HA glycoprotein, both antigenic shift and antigenic drift necessitate new 
vaccine development every season (22). Not only is this process onerous and 
expensive, the need to predict which circulating strains will dominate in any given 
season often leads to reduced vaccine efficacy in seasons where predictions were 
incorrect and when pandemic strains arise (44, 45).  
 
B. Influenza Vaccination: Inactivated Influenza Vaccines (IIV) and 
Recombinant Vaccines 
 IIV have been used since the 1940s and are the most commonly 
administered influenza vaccines. Traditionally these have been trivalent vaccines 
including Influenza A H1N1, H3N2 and an Influenza B strain. Recently, 
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quadrivalent vaccines have been approved that include both circulating Influenza 
B lineages (18, 46). IIV include whole, split (treated with ether/detergent), and 
subunit (semi-purified HA and NA) vaccines (47). Production of these vaccines is 
a lengthy process involving passage of viral stocks in embryonated eggs. Given 
this onerous development process, the emergence of pandemic strains is 
extremely problematic in that a novel IAV strain would be able to spread much 
more rapidly than our ability to respond and generate a specific vaccine. 
 In 2013, a trivalent (replaced in 2016 by a quadrivalent) cell-based, IIV 
(ccIIV3 and ccIIV4) was licensed for use in the US. Flucelvax is produced via the 
passage of virus through Madin-Darby Canine Kidney (MDCK) cells in culture (48). 
This platform has several benefits including being safe for those with egg allergies, 
not being limited by embryonated egg supply, and eliminating the potential for egg-
adapting mutations that may occur during passage through embryonated eggs 
(49). Although not an IIV, a recombinant HA vaccine (Flublok) has also been 
approved for use in the United States. In this system, purified HA is expressed in 
insect cells using a baculovirus expression system (50). Adaption of new platforms 
like these will be critical moving forward to increase or ability to rapidly generate a 
vaccine should an unexpected pandemic strain arise. 
  
C. Influenza vaccination: Live attenuated Influenza Vaccine (LAIV) 
 LAIV consists of a cold-adapted, attenuated live virus. Like IIV, seasonal 
predictions are made to select an H1N1, H3N2, and either one (trivalent) or two 
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(quadrivalent) Influenza B lineages. The HA and NA of each virus is then inserted 
into a cold-adapted, temperature sensitive backbone derived from A/Ann 
Arbor/6/60 and B/Ann Arbor/1/66 viruses (51). These viruses replicate in the upper 
respiratory tract but not in the lower respiratory tract providing a limited amount of 
virus replication to stimulate the innate immune system and allow for processing 
of Ag for T cell recognition (52, 53). 
LAIV was first licensed for use in the US in 2003 and since then has been 
very commonly used, particularly in children. However, in June 2016, the CDC’s 
Advisory Committee on Immunization Practices decided to not recommend 
vaccination with LAIV for the 2016-2017 flu season. Although it has been well 
established that these vaccines have limited efficacy in adults as pre-existing 
immunity prevents replication of the attenuated virus, there have been many 
studies showing increased effectiveness in children compared to IIV (18, 54–56). 
However, in the 2010-2011, 2013-2014, and 2015-2016 seasons, LAIV 
underperformed compared to IIV in protecting against circulating H1N1 in children 
ages 2-17 (48, 57). The reason for this unreliable efficacy is unclear, however 
disparities between the efficacy of different vaccine shipments within the same flu 
season suggest that vaccine handling may have been a cause (57).  
 
D. Influenza vaccination: Universal Influenza vaccine 
 All currently licensed influenza vaccines fail to generate broadly protective 
responses. Current methods for measuring the efficacy of vaccines rely heavily on 
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hemagglutination inhibition (HAI) assays that measure the concentration of serum 
Ab that blocks HA binding to sialic acid on red blood cells (RBC). Therefore, this 
assay will only detect Ab that interfere with sialic acid binding, presumably via 
binding the globular head (HA1 subunit) of the HA molecule. While these Ab are 
likely to neutralize the virus by preventing receptor binding and viral entry, they are 
also likely to only recognize the immunizing strain, as this region can undergo 
extensive mutation without affecting viral fitness (22). There are efforts to develop 
broadly reactive (within a given subtype) Ab against the receptor binding region of 
the HA. This involves the use of various methods of sequence analysis to develop 
a synthetic HA molecule with shared or “centralized” sequences among all the 
known viruses within a given subtype (58–60).  
 The stalk region, made up mostly of the HA2 subunit, is far less tolerant of 
mutations than the globular head due to its critical function during viral fusion. The 
stalk region is fairly conserved and therefore Ab that target this region have broad 
reactivity, generally among an entire phylogenetic group of HA molecules (61–64). 
Unfortunately, stalk reactive Ab are not as immunodominant as those generated 
against the globular head and are not generated by current IIV vaccination (65–
67). However, they are generated following infection with live virus (65, 68, 69) as 
well as following vaccination with pandemic H5, H7, and swine H1 strains (65, 70–
72). Presumably, when the immunizing Ag includes a globular head that has never 
been seen by the immune system (as is the case with pandemic strains) the low 
levels of pre-existing cross-reactive stalk specific Ab are favored over the primary 
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anti-globular head response which is likely to be delayed (47). This discovery has 
led to efforts to generate vaccines with chimeric HA constructs that include an 
exotic globular head (generally from avian IAV) attached to the H1 stalk region. 
Following serial immunizations with chimeras using different globular head 
constructs attached to the same H1 stalk region, stalk specific Ab can be 
continually boosted. So far, this immunization regimen has only been tested in 
mice and ferrets (73, 74). One important component of any vaccine aimed at 
boosting anti-HA stalk Ab is to ensure that the Ab being boosted has a similarly 
inhibitory function across different influenza subtypes. There have been instances 
were a stalk binding Ab actually aided viral fusion and exacerbated disease (75). 
 Another promising target for universal vaccine design is the highly 
conserved ectodomain of M2 (M2e). Although on its own it is a poor immunogen, 
several groups have had success generating constructs to increase the 
immunogenicity of this small 22-23 amino acid domain in rodent models of 
vaccination (76–80). 
 Influenza T cell epitopes are much more highly conserved than influenza 
Ab epitopes (81). This is due to the fact that many T cell epitopes are derived from 
highly conserved internal viral proteins (81–84). Given this, one would predict that 
some memory T cells generated following live infection would be cross-reactive 
against pandemic influenza strains. Indeed, many studies have shown that 
infection and/or vaccination with seasonal influenza strains generate memory T 
cell responses that cross-react against previously un-encountered pandemic 
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strains (82, 85–91). Studies testing PBMC of healthy donors find the highest 
frequency of cross-reactivity for both CD8 and CD4 T cells in the influenza M1 
protein, with significant responses also seen against NP and PB1 epitopes (15, 84, 
86).  
 Current efforts to develop a T cell based universal vaccine have made use 
of recombinant, replication-deficient Modified Vaccinia virus Ankara (MVA) which 
is a highly attenuated virus that has been used as the “boost” step in many prime-
boost regimens. Since most adults have been previously exposed to influenza, 
MVA (encoding influenza NP and M1) is administered in an effort to “boost” pre-
existing memory T cell populations (92–94). Thus far, this platform has had 
success in boosting cross-reactive T cell memory in clinical trials in both 18-45 
aged cohorts as well as in the elderly (92, 95–97). Additionally, a small, preliminary 
study has shown that the MVA-NP+M1 vaccine can reduce viral shedding and 
symptom prevalence after challenge with a virus against which volunteers had no 
pre-existing neutralizing Ab (as determined by HAI Ab titers) (98). Importantly, one 
dose of vaccine appears to be enough to boost pre-existing T cell populations 
therefore obviating the problem of vector-directed immunity (99). For infants 
lacking pre-existing T cell immunity, a strategy using both adenovirus and MVA 
vectors to perform a prime/boost regime has been tested in mice (100).  
A few other T cell based vaccines have had some success in phase I clinical 
trials. The Multimeric-100 vaccine comprised of conserved linear epitopes from 
HA, NP, and M1 has been shown to be safe and immunogenic (101). Another 
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vaccine comprised of several conserved polypeptides consisting of CD8 T cell 
epitopes was found to be somewhat immunogenic but did not appear to result in 
decreased symptoms or viral shedding following influenza challenge (102, 103). 
While DNA vaccines have had more success in mouse models than in larger 
animals (104), a phase I clinical trial has demonstrated safety and some 
immunogenicity in humans (105). Phase I clinical trials have also been completed 
using a simian adenoviral vector expressing NP + M1 as well as using a 
recombinant virus-like particle (VLP) including HA, NA, and M1 (106, 107). Finally, 
single-cycle infectious influenza viruses (sciIV) have demonstrated T cell-
dependent heterosubtypic protection in both mice and ferrets (108–110). Peptide 
vaccination has also had some success in providing heterosubtypic protection in 
mice. It however remains to be seen how effective they will be in clinical trials. 
 
E. Influenza Vaccination: Mediators of protection: Sterilizing Immunity 
Sterilizing immunity is defined as an immune response that completely 
eliminates infection. This can be achieved through preventing viral receptor 
binding, fusion, replication, or budding. While HAI titers are used as the main 
correlate of sterilizing immunity, other Ab specificities can also provide sterilizing 
immunity. For example, Ab specific for the HA stalk can neutralize virus by 
preventing the cleavage of HA0 into the HA1 and HA2 subunits. They can also 
inhibit the conformation change of HA that is required for successful fusion thereby 
preventing the virus from successfully infecting the host cell. Additionally, stalk-
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specific Ab may interfere with viral budding, preventing cell to cell transmission and 
viral propagation. 
Additionally, it should not be overlooked that Tfh are required for the 
generation of long-lived plasmablast and memory B cell formation. Indeed, studies 
have found that induction of influenza-specific CD4 T cells with a Tfh signature 
strongly correlate with neutralizing Ab titer as well as protection (111, 112). Studies 
suggest that the sterilizing Ab produced by seasonal vaccination may only last for 
about 6 months (70). While this is acceptable for our current seasonal vaccination 
system, if the goal is to move toward more broadly neutralizing and long-lasting 
vaccines, a focus on inducing sufficient Tfh formation should be a top priority.  
 
F. Influenza Vaccination: Mediators of protection: Limiting disease severity 
 Given that often the morbidity and mortality associated with influenza 
viruses is correlated with the extent of disease pathology, the potential for inducing 
immune responses that limit disease severity is an important protection 
mechanism that deserves serious consideration. Both cell-mediated and non-
neutralizing Ab responses can provide protection by limiting viral propagation and 
overall disease severity.  
 One main mechanism by which non-neutralizing Ab provides protection is 
via antibody-dependent cell-mediated cytotoxicity (ADCC) (78, 113–115). This is 
a process in which viral Ag on the surface of an infected cell is bound by Ab. 
Natural killer (NK) cells recognize the Fc region of the Ab and kill the infected cell 
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through the release of lytic enzymes (116). Other mechanisms that are especially 
important for protection mediated by anti-M2e Ab are antibody-dependent cell-
mediated phagocytosis and complement dependent cytotoxicity (78, 80, 115). 
Although these mechanisms do not block initial infection, they do limit viral 
propagation and can therefore have  a dramatic effect on protection (78, 113–115).  
 While T cell responses cannot neutralize the virus, there is substantial 
evidence that T cells can provide heterosubtypic protection by limiting the severity 
of disease. Many mouse studies have shown that both CD8 and CD4 T cells can 
mediate heterosubtypic protection (2, 3, 83, 117, 118). Additionally, various human 
studies have shown that cross-reactive T cell responses correlate with decreased 
disease severity (119–122). One study in particular found that cross-reactive CD4 
T cells with cytotoxic function correlated with decreased disease severity following 
influenza challenge in humans (120).  
Although current seasonal LAIV has fallen short of expectations likely due 
to manufacturing problems as well as adult pre-existing immunity preventing viral 
propagation as evidenced by decreased viral shedding and low immunogenicity 
(44, 56, 123), it’s success in boosting broadly reactive protection can be attributed 
to its superior induction of T cell responses (52, 53, 124–127). The similarity to 
viral infection of LAIV may be what drives its success in initiating T cell responses. 
One study demonstrates that viral infection is best at generating multiple cytokine 
producing CD4 T cells, a characteristic shown to mark functional superiority (128), 
suggesting that a vaccination scheme that mimics live viral infection may be the 
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best way to generate potent memory CD4 T cells (129). Although vaccine delivery 
may need to be re-worked, it is clear that inducing T cell responses is a worthwhile 
effort in that they can prevent severe disease in the absence of neutralizing Ab.  
 
T cell Response to Influenza 
 
A. T cell Response to Influenza: Antigen Presentation 
 Activation of the T cell response is initiated largely by migratory 
CD11c+CD103+ and CD11c+CD11b+ respiratory dendritic cell (RDC) populations. 
RDC are resident in the lung and upon uptake of Ag (either by endocytosis of viral 
particles and/or dead cellular debris, or direct infection) migrate to the SLO and 
present Ag to naïve T cells. The extent to which direct viral infection of dendritic 
cells (DC) is required for T cell responses is unclear. CD4 T cells recognize 
epitopes bound to MHC-II which are loaded in endosomal compartments (130). It 
is therefore traditionally thought that CD4 T cell epitopes are derived from 
endocytosis of viral particles or cellular debris from infected cells. However, a 
recent study found that processing of endogenous Ag rather than exogenous Ag 
mediated CD4 T cell responses following influenza infection (131). This study 
suggests that rather than originating from the endosomal compartment, presented 
Ag likely originates from the cytosol indicating a critical role for direct viral infection 
of antigen presenting cells (APC).  
However, determining if an APC population is infected in vivo is somewhat 
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difficult, many studies rely on IAV-GFP reporters to identify virally infected cells. 
Unfortunately, these reporters cannot distinguish between infected cells and cells 
carrying endocytosed viral material (132, 133). A few studies have employed 
methods to address this, including staining for surface HA (one of the first proteins 
to be expressed on the surface of virally infected cells) and use of a hematopoietic 
miRNA targeted against viral NP that specifically limits viral replication in APC. The 
study using surface HA staining to mark virally infected cells demonstrated that 
CD103+ and CD11b+ RDCs present in the DLN 48 hours post infection were NS1-
GFP+, indicating a significant amount of intracellular NS1, but were surface HA 
negative, suggesting that they were not infected (134). They went on to suggest 
that these DCs were protected from infection via a Type I IFN-dependent 
mechanism (134). A study using hematopoietic specific miRNA found that CD8 T 
cell responses were not altered when viral replication was inhibited in APC, 
suggesting that presentation of exogenous Ag via cross-priming of CD8 T cells 
was sufficient (135). However, endogenous Ag processes may play a role in Ag 
encounter of effector T cells in the lung because lung macrophage populations can 
be infected (134) and MHC-II is upregulated on lung epithelia following infection 
(14). While the mode of Ag uptake by migratory DC is still up for debate, studies 
comparing CD4 T cell activation following inactivated versus live virus have clearly 
demonstrated that infectious virus is required to initiate an effective CD4 T cell 
response (131). 
Once migratory DC enter the DLN, they can transfer Ag to LN resident DC 
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populations although the extent to which this is required for the generation of the 
T cell response is unclear (136). While both CD103+ and CD11b+ DC present Ag 
early to initiate priming in the DLN, CD11b+ DC peak at 5 days post infection (dpi) 
in the DLN and 7 dpi in the lung suggesting that Ag encounters at the effector stage 
of the response are likely mediated by this subset (137). It was shown that CD11b+ 
DC effectively endocytose viral Ag and are able to present to CD8 T cell via cross-
priming (137–139), given that the classical MHC-II Ag presentation pathway 
includes processing of exogenous Ag, it is likely that these cells are able to present 
Ag to CD4 T cells as well. 
 
B. T cell Response to Influenza: Kinetics of the T cell Response 
 Migratory DC arrive in the lung about 24 hours after infection and by day 3 
of infection virtually all Ag-specific T cells have been stimulated with Ag in the 
secondary lymphoid organs (SLO) but have not yet begun to proliferate. At 4 dpi, 
T cells have undergone several rounds of division and a few cells begin to migrate 
to the lung around 5-6 dpi (140). Both CD4 and CD8 T cells peak in the lung around 
8-9 dpi (14, 141). Following the peak of infection, CD4 T cells sharply contract and 
form a stable memory population by 20 dpi (1) (Figure 1.2). The contraction of CD8 
T cells is a bit more delayed particularly in the lung and BAL (141). Viral titer peaks 
around 4 dpi and is cleared by 10-12 dpi (141) (Figure 1.2). 
 The primary effector CD4 T cell response is heterogeneous, and is   
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Figure 1.2. Kinetics of the CD4 T cell response to influenza. 
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Figure 1.2 Kinetics of the CD4 T cell response to influenza. 
 
 
5x104 naïve OT-II.Thy1.1+/  were transferred to B6 mice followed by infection with 
a sublethal dose of PR8-OVAII. OT-II cell numbers are enumerated on the left y-
axis over the course of the response. IAV PA copy number per lung is enumerated 
on the right y-axis over the course of the response. The limit of detection refers to 
the PA copy number reading of uninfected B6. OT-II cell numbers peak at day 9 of 
infection. Virus is cleared by day 13 of infection.  
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composed of Th1, SLO-restricted T follicular helper cells (Tfh), and lung-restricted 
cytotoxic CD4 T cells (ThCTL). A Th1 phenotype predominates in all organs with 
T-bet expression and IFNg production being present in the lung, spleen, and DLN. 
Lung cells largely produce IFNg with little IL-2 and TNF, whereas CD4 T cells in 
the SLO produce IFNg, IL-2, and TNF (4, 14, 140). The IAV Ab response is highly 
dependent on CD4 T cells (6), and the generation of long-lived plasma cell 
formation requires CD4 T cell expression of SAP (7). In addition to the Tfh-
mediated germinal center reactions, CD4 T cells promote an early IgA response 
(6).  CD4 T cell “licensing” of DC via CD40-CD40L interactions helps CD8 T cells 
overcome Treg suppression (8). CD4 T cells also promote CD8 T cell memory 
formation and recall responses (9, 10). Additionally, CD8 T cell resident memory 
localization and function requires IFNg production by CD4 T cells during IAV 
infection (11). Finally, lung restricted ThCTL can mediate direct killing of infected 
cells resulting in reduced weight loss and protection in the absence of Ab (4, 13, 
14). 
 
C. T cell Response to Influenza: Memory T cells 
 A heterogeneous population of memory CD4 T cells is generated following 
influenza infection (4, 142). Memory CD4 T cells enhance innate immune 
responses in the lung (12). They provide enhanced B cell help compared to naïve 
CD4 T cells. They provide CD8 T cell help and, via IFNg, provide direct protection 
against lethal IAV (3). Upon activation, memory CD4 T cells accumulate in the lung 
	 26	
to a greater extent than do primary CD4 T cells and have greater multi-cytokine 
producing potential (2). Additionally, whereas Tfh are restricted to the SLO during 
the primary response, during a secondary response, Tfh can be found in the lung 
(2). 
 Recent work has demonstrated the increased protective ability of tissue 
resident memory T cells (Trm) (5, 53, 143). Teijario et al. found that memory CD4 
T cells isolated from the lung provided superior protection when compared to 
memory CD4 T cells isolated from the spleen (5). CD8 Trm can be identified by 
CD103 and CD69 expression, CD4 Trm are identified by high CD69 expression  
and a slight upregulation of CD11a (LFA-1) (5, 143). While it has been shown that 
CD8 Trm require Ag presentation in the lung (144) as well as CD4 T cell help (11), 
little is known about what regulates CD4 Trm formation following influenza 
infection.  
Tfh memory has been identified in several infections and circulating 
influenza-specific Tfh-like memory cells can be found in the human population 
(111, 112, 145–147). Interestingly, memory CXCR5+ CD4 T cells retain some 
plasticity upon secondary infection. Instead of being restricted to Tfh differentiation, 
they are able to differentiate into multiple different subsets (147–149). It is likely 
that the heterogeneity of memory CD4 T cells is critical to protection and more 
work is needed to fully elucidate the requirements for the generation of each 
subset. 
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Factors that Govern T cell Responses 
 
A. Factors that Govern T cell Responses: Contraction 
Overview 
 The T cell response terminates with the apoptosis of around 90% of 
responding T cells leaving a small population of memory T cells. Therefore, 
surviving this stage of the response is critical for memory formation. There are 
several processes that have been proposed to regulate the cell death that occurs 
during this stage. The major proposals involve extrinsic or death receptor-mediated 
cell death and intrinsic or Bcl-2 family member mediated cell death (150, 151). The 
following subsections will examine the proposed role for both of these pathways in 
contributing to cell death during the termination of the T cell response. A 
mechanism involving the death receptor pathway is activation induced cell death 
(AICD) in which activated T cells undergo apoptosis when re-encountering Ag. 
Although some reports have shown this can occur in a death receptor-independent 
fashion (152, 153), the majority of studies demonstrate this is a death receptor 
(Fas or CD95 in particular)-driven mechanism (154–161). The intrinsic cell death 
model involves programmed or passive cell death in which activated T cells die at 
the end of the immune response due to the withdrawal of critical survival factors 
(162, 163).  
 
Activation-induced cell death (AICD) 
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AICD describes the phenomenon of activated T cells undergoing cell death 
when re-stimulated. With the exception of a few studies suggesting a role for 
granzyme B or hematopoietic progenitor kinase 1 (HPK1) (152, 153), the term 
AICD is used to describe a Fas (CD95)-mediated mechanism of cell death (154–
161). Most of these studies examine in vitro-generated effector T cells cultured in 
the presence of exogenous IL-2. Since IL-2 has been shown to sensitize T cells to 
AICD (157, 164), these conditions may cause in vitro-generated effector T cells to 
be more susceptible to AICD than in vivo-generated effector T cells.  
The role of AICD in vivo is unclear. Fas-mediated AICD seems to play a role 
in maintaining peripheral tolerance, limiting autoimmunity, and superantigen-
mediated deletion (165–167). Some reports find AICD of human activated T cells 
during HIV infection (168). Additionally, some have found a role in Fas-mediated 
cell death in regulating T cell contraction during persistent lymphocytic 
choriomeningitis virus (LCMV) infection (169). However, Fas-mediated AICD 
appears to have limited to no role in regulating T cell contraction following acute 
viral infection (165, 166, 170, 171). Given that the models in which AICD appears 
to be important are those in which Ag stimulation is very strong (superantigen) 
and/or continuous (autoimmunity and persistent infections) or in the presence of 
unphysiological levels of IL-2 (in vitro generation of effectors), it is likely that an 
acute viral infection does not generate effectors that are as susceptible to AICD. It 
is also unclear how extensive Ag re-encounter is during the effector phase of the 
response, an issue that is addressed in this thesis. 
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Programmed or Passive Cell Death 
 Programmed or passive cell death involves intrinsic cell death mediated by 
the Bcl-2 family members discussed in the following subsection. It is also often 
referred to as cytokine or survival factor withdrawal. The rationale for this model is 
that T cell activation induces many pathways involved in cell death (172), and 
cytokines are needed to counterbalance these effects by providing survival signals. 
Studies demonstrating that responding T cells required cytokines in addition to 
TCR stimulation and co-stimulation for survival (173–176) led to the hypothesis 
that as pathogen decreases and T cell numbers expand, survival inducing 
cytokines may become limiting, leading to the default death of effector T cells (150, 
162, 163). While one study found that Ag can promote the survival of effectors late 
in the response (177), it is generally believed that inflammation induced cytokines 
promote the survival of effector T cells even in the absence of Ag (178, 179).  Some 
of the key factors in this process including Bcl-2-interacting mediator of cell death 
(Bim), IL-7, and IL-2 are discussed further below.  
 
The role of Bim during contraction. 
 Bim is a member of the B cell lymphoma 2 (Bcl-2) family of proteins that 
mediate intrinsic cell death. Intrinsic cell death is initiated by growth factor 
deprivation, stress, UV, or viral infection. It is a mechanism that leads to pore 
formation in the outer mitochondrial membrane leading to release of cytochrome c 
and Second Mitochondria-derived Activator of Caspase (SMAC, also known as 
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DIABLO) resulting in caspase 9 activation, ultimately leading to caspase 3 
activation and cell death.  
 The Bcl-2 family of proteins can be further differentiated into three classes 
based on their expression of Bcl-2 homology domains 1-4 (BH1-4). The first 
includes the anti-apoptotic proteins including Bcl-2, Bcl-XL, Bcl-w, A1, and myeloid 
leukemia cell differentiation protein 1 (Mcl-1) which include BH1-4. The second 
class includes pro-apoptotic molecules that contain BH1-3, including Bcl-2-
associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) which are 
the two proteins directly involved in pore formation in the outer mitochondrial 
membrane (180, 181). The final class is the BH3-only proteins, including Bim, Bcl-
2 antagonist of cell death (Bad), and Bcl-2-interacting killer (Bik), Bcl-2 interacting 
domain death agonist (Bid), Bcl-2 modifying factor (Bmf), Bcl-2/adenovirus E1B 
19KD protein-interacting protein 3 (pNIP3), Harakiri (Hrk), Noxa, and p53-
upregulated modulator of apoptosis (Puma) (182–184). These proteins are thought 
to act by binding class I anti-apoptotic Bcl-2 proteins and blocking their inhibition 
of Bax and Bak (184, 185). However, Bim and Bid have also been shown to directly 
activate Bax and Bak (180, 185, 186). 
 The pro-apoptotic protein Bim and anti-apoptotic Bcl-2 have been shown to 
play a dominant role in T cell survival with the ratio of these two determining the 
level of  naïve T cell survival (187, 188). Additionally, the overexpression of Bim 
promotes effector T cell death and contraction is significantly reduced in Bim 
knockout T cells (171, 189–191). Importantly, although some studies have 
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suggested a requirement for Bim in activation of autoreactive T cells (192), Bim 
knockout cells are able to proliferate and are functional following pathogen 
challenge (189, 191). The regulation of Bim expression during T cell activation is 
fairly complex. Studies have demonstrated that it is increased following TCR 
stimulation (193). Others have shown that Foxo3a promotes the expression of Bim. 
Since phosphorylated AKT (pAKT) [downstream of, among other things, the TCR 
(194)] leads to phosphorylation of Foxo3a, resulting in its exit from the nucleus and 
sequestration in the cytoplasm preventing the transcription of its targets, it is 
possible that TCR signaling can directly lead to decreased Bim expression as seen 
in memory CD4 T cells (195). Additionally, Id2 is thought to inhibit Bim expression 
(196), since Id2 expression is regulated by STAT4 and STAT5 (197), there is a 
potential mechanism by which cytokines can inhibit Bim expression in addition to 
promoting Bcl-2 expression (198). Although Bim is an important mediator of cell 
death during contraction, more work must be done to elucidate what the key 
signals are that regulate its expression during a T cell response. 
 
IL-7 and its receptor CD127 during contraction and memory formation. 
  CD127 is the alpha subunit of the IL-7 receptor. IL-7 is critical for the long 
term survival of memory T cells (189, 199, 200). The role of IL-7 in regulating the 
generation of memory CD4 T cells is unclear. Studies have shown that blocking 
IL-7 prior to memory formation had no effect on contraction during Vaccinia or 
LCMV infection (201, 202), it did however, limit memory formation of secondary 
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effectors during influenza infection particularly in the SLO (1). Given the near 
uniform upregulation of CD127 on memory CD4 T cells it is clear that it is an 
essential marker of memory formation (203). 
 Although CD127 marks memory precursor effector CD8 T cells (204), it is 
unclear to what extent it predicts memory formation of CD4 effector T cells. 
Although a study of secondary effectors found that CD127 expression at the 
effector stage correlated with cells that would form memory (1), since secondary 
effectors express more CD127 than do primary cells (2), it is unclear whether or 
not this is the case in the primary response. In fact, a study in which CD127h  and 
CD127 o CD4 T cells were sorted at the effector stage and transferred to infection-
matched hosts showed no difference in their ability to become memory (205). This 
was due to the ability of CD127 o cells to upregulate CD127 during the termination 
of the response. While the role of CD127 expression in selecting which effector 
CD4 T cells become memory is unclear, it is clear that memory CD4 T cells 
upregulate CD127 expression (203, 205) and are dependent on IL-7 for their 
maintenance (189, 199, 200).  
 
The role of IL-2 in memory T cell formation. 
 IL-2 signaling during priming is critical for CD4 and CD8 memory T cell 
formation (206, 207). Conversely, IL-2 signaling during priming can also lead to 
terminal differentiation and increased susceptibility to AICD (157, 164, 208). 
Similarly, increased CD25 expression on early CD8 effectors is thought to mediate 
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increased IL-2 signaling leading to terminal differentiation (208). In CD4 T cells, 
early CD25h  effector cells are thought to be driven toward Th1 differentiation as 
opposed to Tfh differentiation (149). Although there is some similarity in that Tfh-
like cells are thought to give rise to central memory cells (148, 149), Th1 cells are 
also capable of becoming memory (148, 209) and therefore are not terminally 
differentiated. 
 Timing is likely critical in determining the outcome of IL-2 signaling. Studies 
that examine late IL-2 signaling largely conflict those that examine early IL-2 
signaling. For example, in CD8 T cells, studies suggest that IL-2 signaling late 
during the response promotes memory formation of CD8 T cells (210, 211). When 
CD25h  and CD25 o CD8 T cells are sorted at day 8 of LCMV infection and 
transferred to infection-matched hosts, CD25h  cells formed memory to a greater 
extent than did CD25 o cells (210). Additionally, addition of exogenous IL-2 late 
during LCMV infection boosts CD8 memory T cell formation (211). Studies from 
our lab have shown that effector CD4 T cells could be rescued from programmed 
apoptosis with the addition of IL-2 and TGFb in vitro (212). Additionally, McKinstry 
et al. showed that IL-2 was required from day 5-7 of influenza infection for CD4 
memory T cell formation (1). 
 
B. Factors that Govern T cell Responses: CXCR3 and memory T cells 
 CXCR3 is a chemokine receptor that is expressed on effector and memory 
T cells. It is upregulated on CD4 effector and memory cells following Th1-inducing 
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inflammation, and is regulated by the Th1 transcription factor T-bet (213, 214). Its 
ligands include CXCL9, CXCL10, and CXCL11 that can be induced by IFNg. 
CXCL10 can also be upregulated by IFNa/b as well as NF-kB induction (215, 216). 
Therefore, CXCL10 is preferentially expressed following TLR ligation. During 
priming, CXCR3 is critical for effective Th1 differentiation and for migration of Ag-
specific T cells out of the T cell zone into the interfollicular (site of T cell and DC 
interactions) and medulla (site of drainage of soluble Ag) regions (217). It is also 
critical for directing activated T cells to peripheral sites of inflammation (218–220). 
 CXCR3 has been shown in CD8 and human CD4 T cells to mark memory 
cells that have a heightened ability to participate in recall responses (221, 222). 
Additionally, CD8 T cell studies have shown that CXCR3+ memory cells are 
preferentially localized in the cortical ridge area near the interfollicular regions 
where they rapidly migrate upon activation (223, 224). Memory CD4 T cells also 
seem to preferentially localize to the cortical ridge (225), although while it is likely, 
it has not been shown that CXCR3 mediates this localization. CXCR3 expression 
in memory CD8 T cells is also critical for lung surveillance and protection following 
influenza infection (226). While this role has not yet been examined in CD4 T cells, 
given that memory CD4 T cells also express CXCR3, it is likely that they migrate 
toward its ligands in a similar fashion. 
 
C. Factors that Govern T cell Responses: Bcl-6 and memory T cells 
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 Bcl-6 is a transcriptional repressor most prominently known for its role in 
promoting Tfh formation (227–229). However, it has been shown to interact with 
T-bet in Th1 cells to modulate Th1 genetic programs (230, 231). For example, 
Oestreich et al. found that during Th1 differentiation T-bet bound Bcl-6 at the 
Socs1, Socs2, Tcf7, and Ifng loci to inhibit gene expression (230). Interestingly, 
the inhibition of IFNg expression by T-bet bound to Bcl-6 was only present late 
during Th1 differentiation, suggesting that the association of T-bet with Bcl-6 may 
play a role in limiting effector differentiation. However, this study was done 
following in vitro Th1 polarization so it is unclear to what extent these interactions 
occur in vivo. 
 Bcl-6 is also important for both CD8 and CD4 memory T cell formation (232–
234). Ichii et al. found that although effector expansion was not affected, Bcl-6 
deficient CD4 T cells were unable to form a long-lived memory population following 
immunization with OVA and LPS (232). They found that Bcl-6 was important for 
cell survival during the late stages of the response. This finding is interesting given 
that Bcl-6 was recently found to play a role in repressing glycolysis which is a 
critical step in transitioning to a resting memory cell that relies primarily on 
oxidative phosphorylation mediated by fatty acid oxidation (235–237). Additionally, 
Bcl-6 knockouts appear to have a decrease in molecules required for fatty acid 
oxidation in adipose tissue (238). Although the role of Bcl-6 in inhibiting glycolysis 
during the transition to memory has not been thoroughly examined in vivo these 
findings are consistent with the fact that Tfh (which express very high levels of Bcl-
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6) utilize glycolysis much less than Th1 cells (239). Thus, although it is clear that 
Bcl-6 plays a critical role in memory T cell formation, more work must be done to 
elucidate what role it plays in mediating the metabolic transition of memory T cells. 
 
D. Factors that Govern T cell Responses: The role of Ag in effector 
generation. 
 In vitro studies have found a very minimal requirement for Ag to program T 
cells to undergo proliferation and gain effector function. The consensus being 
around 24-40 hours of strong TCR stimulation for CD8 T cells (240–244) and 48 
hours of strong TCR stimulation for CD4 T cells (243, 245–248). One recent study 
found that 2 days of aCD3 and aCD28 in vitro was not sufficient for continued 
proliferation of CD4 T cells transferred to mice without Ag (249). The potential 
difference in this study may have been the absence of exogenous IL-2 in the in 
vitro cultures, since IL-2 has been found to be necessary for the survival of cells 
undergoing Ag-independent proliferation in vitro (242, 245, 248, 250). However, 
although cells may continue to proliferate without Ag, some have found that 
proliferation is increased if Ag is present for up to 60-96 hours of culture (247, 251, 
252). 
 Studies in which priming occurred in vivo had more conflicting results. 
Studies using the Listeria monocytogenes (L.monocytogenes) infection model in 
which Ampicillin (Amp) was used to truncate infection at 24 hours resulted in 
conflicting reports from two different groups. In studies from the Harty lab and 
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others, both responding CD8 and CD4 T cells peaked a day earlier than the no 
Amp control and never reached the peak cell number seen in the control (253–
256). However, Bevan and colleagues found that CD8 effector T cell numbers were 
similar, while CD4 T cell numbers were reduced following Amp treatment after 24 
or 48 hours compared to untreated controls (257). Despite these differences, at 7 
dpi (the peak when infection was truncated) both studies found similar numbers of 
CD8 T cells when Amp was used at 24 hours and similar number of CD4 T cells 
when Amp was used at 48 hours compared to untreated control mice, suggesting 
that cells did undergo some Ag-independent proliferation in vivo (253, 257).  
 The use of antibiotics to truncate infection results in a decrease in Ag 
presentation as well as inflammation which has been shown to promote continued 
proliferation of CD8 T cells during L.monocytogenes infection (258). To address 
this caveat, a few studies have examined the role of Ag while leaving inflammation 
intact. One such study found that deleting APC via a diphtheria toxin (DT) system 
at 48 hours had no effect on the numbers of CD8 effector T cells. However, this 
study used the transfer of peptide-pulsed CD11c-DTR APC to initiate a response 
which is unlikely to adequately replicate Ag presentation during pathogen infection 
(259). Using an elegant transgenic mouse strain termed TIM (tet-inducible 
invariant chain with MCC) that expresses MCC93 103-bound MHC-II in an inducible 
manner, Obst et al. found that CD4 T cells do not undergo full autopilot proliferation 
after 2 days of stimulation (249, 260). A caveat that is not fully addressed in these 
studies is that the APC are likely not as activated as those present during pathogen 
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infection. 
 A couple of studies have made use of the Y-Ae Ab that is specific for the 
Ea peptide bound to I-Ab (261) to specifically block Ag recognition to transgenic 
TEa CD4 T cells specific for this epitope. One study used a model with peptide-
pulsed APC, while the other used a VSV recombinant that expressed the Ea 
peptide. The peptide-pulsed APC model showed that Ag was needed beyond 36 
hours for full expansion (262). The VSV model showed that full effector CD4 T cell 
expansion was reached after 4 days of infection (263). It should be noted that 
although the peak of the CD4 T cell response in the VSV model is not shown, it 
appears to be no later than 5 dpi (263). This indicates that Ag was required for 
almost the entire duration of the expansion phase of the response. 
 A few CD8 T cell studies have been done in influenza with mixed results. A 
couple of groups have found that CD8 T cells required Ag stimulation beyond 7 dpi 
for full effector expansion (263, 264). However, although both studies used the 
influenza model WSN-OVAI and measured OT-I recovery at 10 dpi, their results 
differed in the magnitude of the effect. Blair et al. found that blocking OVA-Kb 
resulted in similarly low numbers of effector cells regardless of whether they 
blocked on day 0 or day 7 of infection (263). Dolfi et al. found a very modest 
decrease in CD8 T cells following deletion of CD11c on 6 dpi. They went on to 
show that OT-I effectors isolated at 8 dpi were present at much higher numbers at 
5 days post transfer (dpt) if transferred to WSN-OVAI-infected hosts compared to 
uninfected or PR8-infected hosts. However, 8 dpi OT-I effectors were transferred 
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into 5 dpi infected hosts, this mismatched timing may not accurately replicate what 
occurs during an endogenous T cell response (264). Others suggest there are 
epitope specific differences in the length of the Ag requirement for CD8 T cells 
(138, 139). These studies suggest that CD8 T cells directed against certain 
epitopes are dependent on prolonged Ag presentation that requires cross-
presentation mediated by virus-specific Ab binding FcgR on DC (138, 139). Given 
the differences in MHC-I and MHC-II peptide loading pathways, it is unclear if CD4 
T cells are regulated in a similar way. 
 The fact that, in some in vivo models, T cells require more than 2 days of 
Ag stimulation for full effector expansion appears to contradict findings in vitro that 
suggest that sustained Ag stimulation for more than 2 days is detrimental to 
effector survival (246). However, these differences may be explained by the fact 
that Ag contacts after 24 hours in vivo may be more transient than those in vitro. 
Microscopy studies have illuminated the timing of priming of both CD8 and CD4 T 
cells in the draining lymph node following administration of peptide/APC (265–
269). The initial phase is characterized by multiple transient interactions between 
T cells and DC expressing cognate Ag. During this phase T cells integrate 
successive signals and if they reach a certain signaling threshold they progress to 
the next phase of more stable contacts with Ag/DC which are required to induce 
activation over tolerance (270, 271). After about 24 hours, T cells separate from 
DC and undergo cytokine-driven proliferation (266–268). At this time, occasional 
contacts with DC may be made but they are rare with most T cells regaining their 
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full mobility (267–269). Interestingly, in a study that added a second wave of DC, 
investigators found that CD4 T cells could form stable contacts during this third 
phase (269, 272), however these additional contacts did not result in increased 
proliferation suggesting that proliferation at this time is likely Ag-independent (269). 
For clarity, most of these studies add labeled Ag bearing DCs and Ag-specific T 
cells in a controlled manner and block LN trafficking to synchronize the response. 
It is therefore unclear what the kinetics are during a live viral infection when both 
T cell and Ag-bearing DC migration and numbers are dynamic. 
 Overall, it is likely that initial priming is followed by a phase of Ag-
independent proliferation as in vitro studies found (245) and in vivo microscopy 
studies appear to confirm (266–268). However, this programmed proliferation may 
be for a limited duration and subsequent Ag stimulation may be required for the 
sustained proliferation seen during a pathogen infection. Of course given the 
largely conflicting literature, this is not certain and is likely infection specific. The 
ability for Ag to continue to have a positive influence on effector T cell generation 
is likely dependent on the breaks from Ag stimulation that are likely to occur in vivo 
(266, 273). 
 
E. Factors that Govern T cell Responses: The role of Ag in memory T cell 
formation.  
 The time frame during which memory fate determination is made has been 
a controversial topic. Rather than identifying a point at which fate decisions are set 
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in stone, many studies have revealed steps that inform fate determination, leaving 
open the possibility that future interactions may affect the ultimate fate of a cell. 
There has been some debate about the extent to which naïve T cells are 
predestined for certain effector or memory fates. Studies in both CD4 and CD8 T 
cells have shown that single naïve clones undergo different differentiation patterns 
upon activation likely due to, among other things, TCR avidity (274–278). Work 
from the Allen lab has shown that even cells with similar avidity for cognate Ag 
may undergo different effector and memory differentiation due to their affinity for 
self-ligand (279, 280). However, given that a single cell can differentiate into both 
effector and memory cells (275), and that IFNg-producing effector cells can give 
rise to memory (209, 281), fate determination is likely not solidified at the naïve T 
cell stage. 
 Many of the studies that examined the Ag requirements for T cell 
proliferation also tested the Ag requirements for memory formation. A few studies 
demonstrated that although limiting infection may inhibit effector cell numbers 
generated at the peak of the response, it either had no effect on or increased 
memory cell numbers (138, 139, 253–255, 263). These findings along with others 
led to a model of memory differentiation in which the bifurcation of effector and 
memory cells occurs very early in a response. This early bifurcation model led to 
the belief that molecules that promote effector expansion and differentiation are 
often in opposition to memory cell formation (282). 
 One prominent finding critical to the formation of this model is the 
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observation that when T cells form stable interactions with DC during priming, they 
undergo an asymmetric division. During these stable interactions a supramolecular 
activation cluster (SMAC) is formed between the T cell and DC in which many 
signaling molecules are clustered. The result is that when the T cell divides, the 
daughter closest to the DC will retain more of the signaling molecules that have 
coalesced at the synapse, in addition to T-bet (283) and CD25 (284), both factors 
that when present at higher levels in cells early during the response lead to terminal 
differentiation of effectors (208, 285, 286).  
While this phenomenon is well documented in CD8 T cells, less has been 
done to study the effect of this early bifurcation in CD4 T cells (287). While studies 
suggest that segregation of LFA-1, CD4, IFNgR, STAT1 and in some cells CRTAM 
(284, 288–290) concentrate in the immunological synapse, it is suggested this first 
asymmetric division may mediate Th1 versus Tfh cell fate (291). This is an 
intriguing hypothesis since others have found an early bifurcation of those effector 
destinies (149, 292). Since both these subsets can further differentiate into 
memory cells (149, 293), it is unlikely that this first division is solely responsible for 
memory fate determination in CD4 T cells.  
One prominent feature in CD8 T cell literature is the ability to differentiate 
between short-lived effector cells (SLECs) and memory precursor effector cells or 
(MPECs) that can be defined by their expression of KLRG1 and CD127 fairly early 
on during the T cell response. It was found that when sorted at the effector stage, 
CD127h  CD8 T cells were far more likely to form memory than CD127 o cells (204). 
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Using these markers as a surrogate for memory versus effector differentiation, 
studies of CXCR3 /  CD8 T cells demonstrated less KLRG1 expression due to 
limited migration to sites of greater Ag density (294–296). These observations 
suggested that increased encounters with Ag lead to terminal differentiation of 
effectors (294–296). Although, these studies don’t adequately separate Ag 
recognition from inflammation which can also cause terminal differentiation (285, 
297), so their interpretation is unclear. However, recent findings have underscored 
the fact that these markers do not cleanly define terminally differentiated effectors 
and memory cells. For instance, KLRG1h  cells are present at memory time points 
and have been shown to mediate optimal protection in models of Vaccinia and 
L.monocytogenes (298). It is therefore misleading to assume that factors that 
promote KLRG1 expression are antagonistic to memory formation. 
Unfortunately, CD127 expression at the effector stage is not a reliable 
marker for effector CD4 T cells destined to become memory (205). A study by 
Marshall et al. suggested that Ly6C marked terminally differentiated effector cells, 
however their results were not as dramatic as those seen with CD127 expression 
in CD8 T cells (205). Additionally, Ly6Ch  cells are also present at significant 
numbers at the memory stage and seem to identify a Th1-like memory population 
(148). In fact, many studies have used Ly6C as a memory CD4 T cell marker (299, 
300). It would therefore be similarly misleading to assume that factors that result 
in Ly6C upregulation were antagonistic to memory formation. 
Moreover, there is growing evidence in CD8 T cell studies that Ag 
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recognition during the effector phase, while not affecting memory cell numbers, 
enhances the function of memory cells (137–139, 144, 301). During influenza 
infection, if Ag was blocked after 7 dpi, certain CD8 T cell specificities were unable 
to optimally proliferate, produce cytokines, and protect following secondary 
infection (138, 139). This is despite forming similar numbers of memory cells with 
a similar CD127 and KLRG1 phenotype (138, 139), further suggesting that these 
markers are of limited utility.  Others have shown in a vaccination model that 
adding additional Ag 5 days after immunization results in efficient memory CD8 T 
cell generation (302, 303). 
Although no CD4 T cell studies examine the role of Ag beyond the priming 
phase, there are studies that suggest that stronger TCR stimulation favors memory 
CD4 T cell formation (304, 305). Williams et al. found that SMARTA transgenic T 
cells specific for the gp61 epitope were able to form memory during LCMV infection 
but not during Listeria Monocytogenes-gp61 (LM-gp61) infection despite 
substantial effector expansion. They found this correlated with a reduced functional 
avidity of SMARTA cells compared to endogenous cells in LM-gp61 infected mice 
(304). While this is a largely correlative study, it does explain the observation that 
polyclonal memory populations have increased functional avidity compared to 
effector cells (304). This suggests that there is some selection pressure on TCR 
avidity in determining which clones survive and become memory, an obvious 
candidate being a role for late Ag presentation in selecting which cells become 
memory. Conversely, Blair et al. found that blocking Ag at 4 dpi following VSV 
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infection resulted in more memory CD4 T cell formation (263). However, there 
were very few memory CD4 T cells in the control and no phenotype or functional 
analysis was done. Thus, the role of Ag at the effector phase of the response in 
promoting or inhibiting CD4 memory T cell generation is a largely unexplored area. 
 
Thesis Objectives 
 Memory CD4 T cells provide protection during influenza infection via several 
mechanisms. Through their helper activity they enhance Ab responses (6, 7), CD8 
T cell responses (8–11), and innate responses (12), additionally they are able to 
mediate direct effector function (2, 4, 13, 14). The ability of memory CD4 T cells to 
orchestrate an effective immune response combined with the fact that many T cell 
epitopes are derived from highly conserved IAV proteins make them ideal targets 
for vaccination. However, vaccination strategies are stunted by our lack of 
understanding of the mechanisms that govern the formation of a large, functional 
CD4 memory T cell population. Efforts to illuminate the mechanisms involved in 
this process could have great implications in rational vaccine design. 
 Current vaccines are generated under the assumption that the Ag 
recognition that occurs during priming is sufficient for CD4 memory T cell 
formation. However, recent studies suggest that Ag recognition during the effector 
phase of the response results in a more functional CD8 memory T cell population 
(138, 139, 144). While the role of Ag recognition at the effector stage in promoting 
CD4 memory T cell formation is unclear, work from our lab demonstrate that 
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autocrine IL-2 signals are required at this time for efficient memory formation (1).  
 I sought to examine the role of Ag recognition at the effector phase of the 
response, termed “late Ag” in shaping the ongoing CD4 T cell response and 
promoting CD4 memory T cell formation. I found that Ag recognition was required 
for full expansion of CD4 effector T cells. Late Ag promoted the survival of 
responding CD4 T cells in a Bim-dependent manner. This pro-survival effect of late 
Ag recognition was significantly decreased in the absence of IL-2 and co-
stimulation. Unlike CD8 T cells (138, 139), the number of CD4 memory T cells was 
significantly decreased in the absence of late Ag. Late Ag promoted the immediate 
expression of CD25, a marker that when expressed late during a response 
correlates with increased ability to form memory (210). It also promoted memory 
associated factors CD27 and Bcl-6. The memory T cells that form in the absence 
of late Ag have reduced memory cell markers CD127 and CXCR3 and have a 
reduced ability to secrete multiple cytokines upon re-stimulation.  
 Importantly, I have established that the signals required late in the response 
can be fulfilled by a short-term Ag/APC population in the absence of virus-induced 
inflammation. The late addition of Ag/APC that are only capable of presenting Ag 
for up to 2 days in vivo was sufficient to restore CD4 memory T cell numbers, 
function, and phenotype in both the lung and SLO. Additionally, when provided at 
6 dpi, this short lived Ag/APC was sufficient to generate a protective CD4 memory 
T cell population. Finally, I demonstrate that adding Ag/APC at 6 dpi can boost 
CD4 memory T cell formation in a cold-adapted immunization model.  
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This late Ag dependent model of CD4 memory T cell formation suggests 
that persisting Ag, indicative of a continuing threat, is required for the commitment 
of resources to memory T cell formation. Additionally, the work presented in this 
thesis establishes the importance in developing vaccines that can provide enough 
Ag to enable Ag re-encounter at later stages of the response.  
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CHAPTER II: Materials and Methods 
Mice 
Naïve CD4 T cells were isolated from OT-II.Thy1.1+/ , OT-II.Nr4a1eGFP.Thy1.1+/ , 
OT-II.Bcl2l11+/ , or OT-II.Osb.eGFP mice bred at the UMMS breeding facility. 
CD11c Tg.H2-Ab1 /  and OT-II.Bcl2l11+/  bred at the UMMS breeding facility were 
used. Hosts were B6 male mice ordered from Jackson Laboratories (JAX). 
Nr4a1eGFP mice originally obtained from JAX were bred at the UMMS breeding 
facility were also used. Mice used in experiments were 8-12 weeks of age. The 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School approved all animal procedures. 
 
Viral Stocks, Infections, and Immunizations 
For all influenza viral infections described, mice were lightly anesthetized with 
isoflurane (Piramal Healthcare) before intranasal infection with 50µL of virus 
diluted in PBS. Influenza A PR8-OVAII and PR8 (H1N1) viruses were produced in 
the allantoic cavity of embryonated hen eggs from stock obtained from Dr. Peter 
Doherty of St. Jude Children’s Hospital. A sublethal dose of 0.3LD50 was used. 
Protection experiments were performed using a lethal dose of 2LD50. Cold-
adapted, attenuated ca.A/Alaska/72/CR9 (H3N2) was originally supplied by S. 
Epstein (NIH, Bethesda, MD) then grown at the Trudeau Institute (83). Mice were 
immunized with 2500 TCID50 ca.Alaska, a dose shown to elicit T cell mediated 
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protection (83). Influenza A/Philippines/2/82/x-79 (H3N2) was supplied by S. 
Epstein (NIH, Bethesda, MD). Mice infected with 100 PFU.   
 
Naïve CD4 T cell Isolation and Effector Generation in Primary Hosts 
Spleens and peripheral LNs were harvested from 6-10 week old TCR transgenic 
or WT mice. Resting cells were enriched using a percoll gradient. CD4 T cells were 
then isolated using CD4 MACS beads (Miltenyi). Naive CD4 T cells were washed 
twice, re-suspended in PBS, and a total of 3x105-5x105 cells were transferred by 
i.v. injection into hosts. Hosts were infected with PR8-OVAII on the same day. 
 
Isolation of 6 dpi Effector CD4 T cells 
Spleen and DLN (Lung Draining Lymph Nodes) were harvested from B6 mice on 
6d after PR8-OVAII infection. Cell suspensions were pooled and donor cells were 
isolated by either Thy1.1 or CD4 MACS isolation (Miltenyi). Cells were 
resuspended in PBS and 1-4x106 effector cells were transferred by i.v. injection to 
hosts. All steps were conducted at RT (except for one 15 minute incubation at 4ºC) 
to maintain effector phenotype. This minimal protocol ensures that effector cells 
are only out of mice for 2.5 hours. 
 
Bone Marrow Dendritic Cell Preparation 
Bone marrow was harvested from B6 mice and washed with RPMI including 1% 
FBS. Cells were plated at 7-8x106 cells/mL in RPMI with 7.5% FBS including 
	 50	
10ng/ml GMCSF. After 7 days, cells were harvested and CD11c+ cells were 
isolated by MACS. Purified cells were then re-plated at 2x106 cells/ml and 
stimulated with Poly I:C at 10µg/ml for 1 day in culture and used as DC. DC were 
harvested, pulsed with 10µM OVAII or NP311 325-peptide at 37ºC for 1 hour with 
shaking. Cells were resuspended in PBS and 3-5x105 cells per mouse were 
injected i.v. 
 
PR8-infected Splenic APC Preparation and In Vitro Culture 
Spleens from PR8-infected B6 mice were harvested 6 dpi. Cell suspensions were 
pooled and washed with RPMI containing 1% FBS. Cells were depleted of Thy1.2+ 
cells using MACS beads. Cells were irradiated with 3000 Rads. This APC 
population was then co-cultured with isolated 6 dpi effectors at a ratio of 5:1 APC 
: OT-II. OVAII peptide was added to culture at 0.5µM. IL-7 was added to cultures 
at 0.1ng/ml (a concentration that does not promote proliferation). All blocking 
antibodies were used at 10µg/ml. 
 
APC for the Protection Experiment 
Spleen cells were harvested from uninfected B6 mice. Thy1.2+ cells were depleted 
using MACS beads. The Thy1.2-depleted fraction was then plated at 3x106 cells/ml 
in RPMI containing 7.5% FBS and 10ng/ml LPS and 10ng/ml dextran sulfate. After 
2 days in culture, these activated APC enriched cells were harvested and pulsed 
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with 10µM OVAII peptide at 37ºC with shaking for 1 hour. APC were transferred to 
hosts with 6 dpi effectors at a ratio of 1:1.   
 
Histology 
B6 mice were infected with 0.3LD50 PR8 or PR8-OVAII. Lungs were harvested at 
6 dpi and fixed in 10% buffered formalin. 10µm sections were taken and stained 
with hematoxylin and eosin (H&E) stain. Lungs were scored as follows: (1) Healthy 
looking bronchioles with consolidation and mononuclear infiltrates comprising 
under 5% of the lung. (2) Mild bronchiolitis with consolidation and mononuclear 
infiltrates comprising over 5% of the lung. (3) Moderate bronchiolitis with 
consolidation and mononuclear infiltrates comprising equal to or greater than 15% 
of the lung. (4) Moderate bronchiolitis with consolidation and mononuclear 
infiltrates comprising equal to or greater than 25% of the lung. (5) Severe 
bronchiolitis with consolidation and mononuclear infiltrates comprising over 50% 
of the lung. Scoring was done blind and four sections of each lung were scored 
and the average is presented. 
 
Viral Titers 
Viral titers of PR8 or PR8-OVAII-infected lungs were determined by quantification 
of viral RNA.  Whole lungs were homogenized in TRIsol/Chloroform (Sigma-
Aldrich) and RNA was extracted using the VWR E.Z.N.A kit and Turbo DNA-free 
kit (Thermo Fisher Scientific). 2.0 µg of RNA was reverse transcribed into cDNA 
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using the High capacity cDNA reverse transcription kit (Thermo Fisher Scientific). 
Quantitative PCR was performed to amplify the acidic polymerase (PA) gene using 
the Bio-Rad CFX96 Realtime PCR system with 50ng of cDNA per reaction. The 
following primers and probe were used: forward primer: 5’CGGTCCA 
AATTCCTGCTGA-3’; reverse primer: 5’-CATTGGGTTCCTTCCATCCA-3’; probe: 
5’-6-FAM-CCAAGTCATGAAGGA GAGGGAATACCGCT-3’. Data were analyzed 
using the CFX Manager Software Version 20 (Bio-Rad). A standard curve 
generated using a PA-containing plasmid obtained from Dr. Rob Webster at St. 
Jude’s Children’s Research Hospital was used to calculate the PA gene copy 
number per 50 ng of cDNA. This was used to calculate the total PA copy number 
per lung.  
 
Flow Cytometry: Cytokine and Other Intracellular Staining 
For cytokine staining, total splenoyctes were stimulated with PMA and Ionomycin 
for 4 hours at 37ºC. Brefeldin A (10µg/ml) was added after 2 hours of stimulation. 
Following a surface stain, cells were fixed in 4% paraformaldehyde and 
permeabilized in 0.1% saponin for 30 min at 4ºC. Cytokines were then stained for 
30 minutes at 4ºC. Bim, Bcl-2, Ki67, Bcl-6, and T-bet were stained using the 
eBioscience Foxp3 staining buffer kit following manufacturer’s recommendations. 
Bim Ab was stained with a fluorescent Goat α-Rabbit Ab from Invitrogen. Host IAb-
NP311 325-specific CD4 T cells were stained with the IAb-NP311 325-APC tetramer 
obtained from the NIH Tetramer Core Facility. All antibodies were obtained from 
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eBioscience except anti-Bim (Cell Signaling) and anti-Bcl-6-PE (BD biosciences). 
Samples were run on LSRII instruments (BD biosciences) and analysis was done 
using Flowjo (Tree Star) analysis software.   
 
Flow Cytometry: Phospho-STAT3 Staining 
After 4 hours of culture, cells were washed with PBS and stained for 20 minutes 
on ice with Invitrogen Live/Dead yellow. Cells were then incubated in BD Fix/Perm 
Buffer for 10 minutes at 37°C. Cells were then incubated in BD Perm Buffer III for 
30 minutes on ice. Finally, cells were stained with fluorescently labeled pY705 
STAT3 Ab (BD Biosciences) for 1 hour at RT protected from light. Samples were 
run immediately after staining. 
 
Microarray Analysis 
RNA was isolated from sorted 6 dpi effector OT-II cells, 6 dpi OT-II cultured in 
media for 2 days, and 6 dpi OT-II cultured with aCD3 and aCD28 for 2 days using 
the same protocol as was used for viral titers. Then a microarray was performed 
using Affymetrix Mouse Gene 2.0 ST arrays by the UMMS Genomics Core Facility. 
The Affymetrix Expression Console was then used for RMA normalization and the 
Affymetrix Transcriptome Console was used to identify genes that were 
differentially expressed by over 2-fold. The NIAID DAVID platform was then used 
to classify genes into functional categories. 
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Statistical Analysis 
 
Groups of at least 3 mice were used for all experiments to ensure sufficient power. 
MFI in all graphs is median fluorescence intensity. For analysis comparing more 
than 2 samples, a one-way ANOVA analysis was conducted with GraphPad prism 
software. To compare 2 samples an unpaired, two-tailed student’s t-test was 
conducted with GraphPad prism software. All data was included unless found to 
be a significant outlier using the Grubb’s test (ESD method) available through 
GraphPad prism software. Welch’s correction was applied when the standard 
deviations were unequal. Significance is indicated by * = P<0.05, ** = P<0.01, *** 
= P<0.001, **** = P<0.0001. 
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CHAPTER III: Late Ag is Required for CD4 Memory T cell Generation during 
Influenza Infection 
 
 
Introduction 
 
While much progress has been made in defining the early activation events 
required for the generation of effector CD4 T cell subsets, the pathways that drive 
a cohort of effector T cells to successfully transition to a memory state remain 
poorly defined. It is unclear to what extent programming during initial cognate 
interaction of T cells with APC determines the fate of effector T cells and if later 
signals affect memory generation.  
Various models defining the role of Ag in effector and memory differentiation 
have been proposed. Some suggest that the initial interaction with Ag/APC is 
sufficient to program a cohort of T cells to become memory and further exposure 
to Ag and inflammation drive terminal differentiation of effector T cells (242, 245, 
251, 253, 282). In contrast, other studies suggest that late Ag enhances the 
function but not the number of memory CD8 T cells (138, 139). It has been shown 
that CD4 T cells require more Ag stimulation for effector and memory generation 
than do CD8 T cells, but most of these analyses have been limited to the priming 
phase of the response (249, 260, 269, 305). Other studies have concluded that 
while prolonged Ag stimulation can enhance effector CD4 T cell proliferation, it is 
deleterious to memory formation (263), and continuous Ag stimulation may drive 
CD4 T cells to a state of reduced responsiveness (246, 300). In vivo, responding 
T cells disengage from APC 24 hours after initial interaction, engaging in few APC 
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contacts during the last phase of priming (266, 269). Thus, it remains unclear how 
often responding CD4 T cells encounter Ag after the initial priming phase of the 
response and if later Ag exposure impacts memory generation.  
During a response to a live pathogen, it would be advantageous for the 
quality and quantity of the effector and memory response to be determined at the 
effector stage when the immune system could sense whether there is still a threat. 
In an in vivo model of IAV infection, our lab recently found that autocrine IL-2 
production by effector CD4 T cells during a defined checkpoint (5-7 dpi) was 
essential to promote survival and memory formation (1). Similarly, addition of IL-2 
complexes late in the response promoted memory formation during LCMV 
infection (211). Since IL-2 production is typically induced by cognate Ag 
recognition, I investigated whether the interaction of effector CD4 T cells with APC 
during this checkpoint is the key event that drives them to make IL-2, to survive, 
and to differentiate into long-lasting memory cells. A defined stage of effector CD4 
T cell development, where CD4 effector fate is determined by cognate Ag 
interaction, would suggest a new paradigm in which the formation of memory 
depends on a cohort of cells being selected by persisting Ag to become memory 
cells.  
In most in vivo studies heretofore, it has not been possible to define the 
necessary timing and duration of the signals needed for the rescue of effectors 
from apoptosis and exessive contraction. Additionally, as T cells reach the effector 
stage, the roles that ongoing infection play in promoting memory have not been 
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definitively examined in an in vivo model of infection. Defining these elements is 
critical for rational vaccine design. 
To address these gaps in our understanding, I use a well-defined model of 
IAV infection to determine the role that Ag presentation and ongoing infection, 
during the effector phase, play in shaping memory CD4 T cell formation. IAV 
induces a highly protective memory CD4 T cell population that synergizes with B 
cells and CD8 T cells to provide protection from challenge with supralethal viral 
doses (2, 3, 14, 120). The response thus epitomizes successful memory CD4 T 
cell generation in response to infection and is therefore well-suited to reveal the 
mechanisms involved in effective memory generation.   
I find that effector CD4 T cells, induced by IAV infection, require cognate Ag 
recognition at 6 dpi for continued expansion, survival, and all but a minor fraction 
of memory generation. In well-controlled adoptive transfer models, I find that 
Ag/APC encounter at the effector stage (6 dpi) enhances the recovery of memory 
cells in SLO and in the lung at least 10 to 100-fold. Notably, other infection-induced 
effects, such as inflammation, are not required for this increased memory 
generation. Effector T cells, exposed to Ag/APC for as little as 2 days, expressed 
higher levels of memory-associated molecules CD25, Bcl-6, CD127, and CXCR3. 
The memory cells generated by Ag encounter between 6-8 dpi had enhanced 
ability to make cytokines and provided better protection against a lethal dose of 
IAV than those that were not exposed to checkpoint Ag. Moreover, in a cold-
adapted vaccine model, I found very little Ag presentation during this late 
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checkpoint, but when additional Ag/APC were introduced at this time, memory CD4 
T cell formation was enhanced. This suggests that low levels of Ag presentation 
from 6-8 dpi may limit efficacy of vaccines that do not provide high levels of 
persisting Ag. These findings imply that whether pathogen infection persists into 
the effector stage determines effector fate by supplying late Ag/APC that are 
needed to program memory formation and that interventions to achieve this need 
not involve long-lived infection and its potentially deleterious effects. 
 
Antigen Recognition at the Effector Phase of Influenza Infection is Limited. 
Previously, it has been difficult to assess exactly when responding CD4 T 
cells encounter Ag in vivo. Transfer of naïve CD4 T cells at various times following 
IAV infection demonstrates that Ag presentation occurs up to 3 weeks post 
infection (306). However, naïve and effector CD4 T cells may have different 
patterns of trafficking. Additionally, in situ effectors may localize to specific niches 
and may not be able to access the same Ag depots that intravenously administered 
naïve cells can. It is therefore unclear if responding CD4 T cells recognize Ag for 
3 weeks post infection. Microscopy studies have suggested that only about ~35% 
of IAV-specific effector CD4 T cells undergo arrest and produce IFNg directly ex 
vivo suggesting recent Ag encounter in the lung at 7 dpi (307). Although this study 
was conducted by transferring in vitro generated Th1 effectors into infected mice 
and was therefore not necessarily representative of Ag recognition by endogenous 
CD4 T cells. To more directly test when responding CD4 T cells recognize Ag in 
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situ, I utilized the Nr4a1eGFP (Nur77GFP) mice that transiently express GFP following 
TCR stimulation (243, 308).  
To determine when responding CD4 T cells encounter Ag in vivo following 
IAV infection, I crossed OT-II.Thy1.1+/  (Ovalbumin323 339 (OVAII)-specific TCR 
transgenic mice) to Nur77GFP mice. To evaluate the feasibility of using Nur77GFP as 
an indicator of recent Ag-induced TCR stimulation in effector T cells, I isolated CD4 
T cells from Nur77GFP mice and stimulated them in vitro. GFP expression was 
rapidly induced and remained high with continued TCR stimulation (Figure 3.1A), 
but was significantly reduced within 24 hours following removal of stimulation 
(Figure 3.1B). Additionally, GFP was rapidly re-expressed following secondary 
exposure to Ag (Figure 3.1C) and did not decrease with division (Figure 3.1D) 
(243).  
To determine the kinetics of IAV Ag recognition in vivo, I transferred naïve 
OT-II.Nur77GFP.Thy1.1+/  cells to C57BL/6J (B6) mice and infected with a sublethal 
dose of A/Puerto Rico/8/34-Ovalbumin323 339 (PR8-OVAII) (Figure 3.2A-3.2D). As 
expected, during priming (3 dpi) most cells were GFP+ indicating recent Ag 
exposure. However, by 5 dpi, only a fraction of effector CD4 T cells had recently 
encountered Ag and by 9 dpi (the peak of the lung effector T cell response) a very 
low percentage of cells express GFP (Figure 3.2C). An examination of the kinetics 
of GFP+ cell numbers demonstrates that the Ag recognition occurs in both the lung 
and SLO and peaks around 7 dpi (Figure 3.2D). The low percentage of GFP 
expressing cells was not due to the transfer of a non-physiological number of OT- 
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 Figure 3.1. Nur77GFP is a reliable reporter of TCR signaling in mature 
effector CD4 T cells. 
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Figure 3.1. Nur77
GFP
 is a reliable reporter of TCR signaling in mature 
effector CD4 T cells. 
  
(A, B) CD4 T cells were isolated from Nur77GFP mice and cultured with anti-CD3 + 
anti-CD28 either continuously for 4 days (A) or removed from stimulation at 48 
hours and re-plated (B). GFP expression was determined by flow cytometry. (C) 
OT-II.Nur77GFP.Thy1.1+/  cells were stimulated in vitro with irradiated OVAII-pulsed 
APCs for 2 days with 5ng/mL of IL-2, then rested for 3 days in culture. Cells were 
then re-stimulated in culture with OVAII-pulsed APC for 2 days. (D) Nur77GFP CD4 
T cells were labelled with cell trace violet (CTV) and stimulated with anti-CD3 + 
anti-CD28 for 3 days in culture. (A-D) Representative data, n=6, 2 experiments.  
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II cells, as a similar GFP kinetics was seen in polyclonal host responses following 
IAV infection of Nur77GFP mice (Figure 3.2E). Thus, effector CD4 T cells only 
intermittently respond to cognate antigen in vivo and the Ag recognition that does 
occur, is mostly limited to just before the peak of the effector T cell response. These 
findings suggest that Ag recognition at the effector stage could act to select a 
limited number of effectors to become memory. 
 Although the GFP median fluorescence intensity (MFI) is lower in the SLO 
than in the lung, it is higher than at the memory time point (31 dpi) (Figure 3.2B). 
Additionally, when OT-II.Nur77GFP cells are isolated at 6 dpi and transferred to 
hosts without Ag (PR8-infected hosts) they do not express GFP (Figure 3.3A). This 
suggests that although it may not be strong TCR stimulation, the GFP signal in the 
SLO at later time points may reflect continuing Ag presentation. Since follicular 
helper CD4 T cells (Tfh) are thought to recognize residual Ag in germinal centers 
(309–311) it is likely that the population that expresses GFP at these later time 
points are Tfh. Indeed, when GFP+ cells are compared to GFP  cells in the spleen 
and DLN, GFP+ cells have higher expression of the Tfh markers CXCR5 and Bcl-
6 at 9 dpi (Figure 3.3B, 3.3C).  
 
Late Ag is Required for Memory CD4 T cell Formation. 
 Since several previous studies have looked at the role of Ag using 
antibiotics to truncate infection resulting in a reduction in both Ag and general 
pathogen-induced inflammation, I sought to examine the role of late Ag using a  
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Figure 3.2. Ag recognition at the effector phase of influenza infection is 
limited.  
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Figure 3.2 Antigen recognition at the effector phase of influenza infection is 
limited. 
 
(A-D) 5x105 naïve OT-II.Nur77GFP were transferred to B6 mice.  Mice were infected 
with PR8-OVAII. Lung, spleen, and DLN were harvested at various time points and 
GFP expression of donor cells was analyzed. (A) Experimental schematic. (B) 
Representative flow cytometry plots of Nur77GFP expression at various time points 
following infection. (C) Kinetics of GFP expression by OT-II.Nur77GFP cells during 
PR8-OVAII infection in B6 mice. (D) Kinetics of OT-II GFP+ cell number. (E)  GFP 
expression kinetics of NP311 325 tetramer+ cells during PR8-OVAII infection of 
Nur77GFP mice. (B, D) Representative data, 4 experiments, n=3-4 each. (C, E) 
Pooled data, n=12-16, 3-4 experiments, mean ± SD. 
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Figure 3.3. Low level Ag presentation late in the SLO marks Tfh. 
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Figure 3.3. Low level Ag presentation late in SLO marks Tfh. 
 
(A) OT-II.Nur77GFP.Thy1.1+/  naïve cells were transferred to B6 mice followed by 
infection with PR8-OVAII. Donor cells were isolated at 6 dpi and transferred to 
either infection matched PR8-OVAII-infected or PR8-infected hosts. Lung cells 
were harvested 18 hours after transfer. GFP expression in the lung is shown. (B-
C) OT-II.Nur77GFP.Thy1.1+/  naïve cells were transferred to B6 mice followed by 
infection with PR8-OVAII. Spleen and DLN were harvested at 5,7, and 9 dpi. (B) 
Representative flow plots of Tfh in GFP+ and GFP  populations at 9 dpi in the 
spleen and DLN. (C) Tfh kinetics between GFP+ and GFP  cells. Representative 
data, 3-4 experiments, n=3-4 each. 
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model that could distinguish between the effects of Ag versus those of the pro-
inflammatory cytokine milieu. To this end, I used the PR8 and PR8-OVAII viruses 
to generate hosts with inflammation alone and inflammation with cognate OT-II Ag. 
To ensure that these infections were similar in aspects other than OT-II peptide 
presentation, I used the IAb-NP311 325 tetramer to measure the NP311 325 specific 
endogenous CD4 T cell response during the course of PR8 and PR8-OVAII 
infection. I found that the CD4 T cell response followed a similar kinetics in both 
viruses (Figure 3.4A). This indicates that with respect to factors that govern the 
CD4 T cell response, these viruses are very similar. Additionally, both PR8 and 
PR8-OVAII infections generated a similar amount of lung pathology at 6 dpi (Figure 
3.4B, 3.4C). Finally, both viruses had similar viral titers at 6 dpi and had cleared 
infection by 14 dpi (Figure 3.4D). 
I next tested if Ag recognition during the effector phase had any effect on 
memory generation. For this, I performed a sequential adoptive transfer 
experiment outlined in Figure 3.5A. I first transferred naïve OT-II.Thy1.1+/  cells to 
B6 mice and infected with a sublethal dose of PR8-OVAII.  At 6 dpi donor OT-
II.Thy1.1+/  effector cells were isolated from the SLO of IAV infected hosts. These 
6 dpi effectors were fully activated, having undergone extensive division as 
evidenced by CFSE dilution, upregulation of CD44, CXCR3, and PD-1 and 
downregulation of CD62L (Figure 3.5B). Donor cells were transferred into 3 groups 
of recipients, also infected 6 days previously with PR8-OVAII (Ag and virus), PR8  
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Figure 3.4. PR8 and PR8-OVAII infections are similar. 
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Figure 3.4 PR8 and PR8-OVAII infections are similar. 
 
(A) B6 mice were infected with 0.3LD50 PR8-OVAII or PR8. The endogenous CD4 
T cell response in the lung was measured at 3, 7, and 14 dpt by staining with the 
IAb-NP311 325 tetramer. Data is representative, n=9, 3 experiments, mean ± SD. (B) 
B6 mice were infected with PR8-OVAII, PR8, or not infected as in (A). On 6 dpi, 
lungs were harvested and fixed in 10% buffered formalin. Pictures are shown of 
H&E stained lung sections at 10X magnification. (C) Pathology scoring of lung 
sections. (D) Viral titer of PR8-OVAII or PR8-infected lungs harvested at 6 dpi and 
14 dpi. Limit of detection determined by uninfected lung results. (A, B) Data is 
representative of 2 experiments, n=3 each, mean ± SD. (C, D) Data is pooled from 
2 experiments, n=3 each, mean ± SD. 
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(virus without Ag), or no virus (Figure 3.5A). I did not include lung effector T cells, 
since they are more likely to have recently encountered Ag (Figure 3.2).  
I enumerated donor cells in the lung, spleen, and draining lymph nodes 
(DLN) at 3, 7, and 14 days post-transfer (dpt). At 7 dpt, there were 60-200x more 
donor OT-II cells in the lung, 15-30X more in the spleen, and 80-400X more in the 
DLN of PR8-OVAII-infected hosts compared to PR8-infected or uninfected hosts 
which were equally poor in supporting donor cell recovery (Figure 3.5C, 3.5D). In 
PR8-OVAII hosts, donor OT-II numbers peaked at 3 dpt (9 dpi) and then contracted 
slowly over the subsequent 12 days (Figure 3.5E) mimicking the endogenous CD4 
T cell response (140) (Figure 1.2). However, in PR8-infected and uninfected hosts 
donor cells underwent a sharp, immediate contraction and by 14 dpt (20 dpi) were 
reduced to close to the limit of detection (Figure 3.5E). A highly significant 
difference in memory recovery was still seen at 53 dpt (Figure 3.5F). These results 
imply that re-exposure to Ag at or after 6 dpi is necessary to maximize the effector 
CD4 T cell response, prevent excessive contraction, and generate a long-lived 
memory population, and that infection without Ag has little if any impact on memory 
formation.  
To test if the ability of Ag recognition to promote memory is transient or 
instead persists to later time-points, I isolated donor OT-II effectors at 14 dpi 
instead of 6 dpi and transferred them to kinetically-matched PR8-OVAII, PR8, or 
uninfected hosts (Figure 3.6A). The presence of Ag in the hosts had little or no 
impact on recovery of these 14 dpi donor cells (Figure 3.6B) indicating that, at 14  
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Figure 3.5. Late Ag is required for memory CD4 T cell formation. 
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Figure 3.5. Late Ag is required for memory CD4 T cell formation. 
 
(A-F) 5x105 naïve OT-II.Nur77GFP.Thy1.1+/  were transferred to B6 hosts. Hosts 
were infected with PR8-OVAII. On the same day, groups of B6 mice were either 
infected with PR8-OVAII or PR8. On 6 dpi, donor OT-II cells were isolated from the 
spleen and DLN of infected mice. 2x106 6 dpi effectors were transferred to the 
PR8-OVAII, PR8, or uninfected hosts. (A) Experimental schematic. (B) 
Representative flow cytometry plots showing the phenotype of isolated 6 dpi OT-II 
effectors compared to naïve OT-II cells. (C) Representative flow cytometry plot 
gated on live cells at 7 dpt. (D) Quantification of donor cell recovery at 7 dpt. (E) 
Kinetics of donor cell recovery in the spleen, lung, and DLN. (F) Quantification of 
cells harvested 53 dpt. Data is representative, n=3-5 each, 3 experiments, mean 
± SD. 
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dpi, CD4 T cells are no longer require Ag recognition for memory formation. 
Interestingly, while 6 dpi effectors underwent extensive proliferation when 
transferred to PR8-OVAII infection matched hosts, 14 dpi effectors failed to 
proliferate in any host (Figure 3.6C). This is despite the presence of Ag 
presentation evidenced by the proliferation of naïve cells (306). I therefore 
postulate that late Ag recognition must occur within a limited time frame in order to 
promote sustained proliferation and survival into memory.  
 
Late Ag is Required for Effector and Memory Formation In Situ. 
To determine if this late requirement for Ag was seen during an intact 
response without the isolation and transfer of effectors, I tested if blocking MHC-
II, during the effector phase of the response, with the anti-IAb Ab (M5114) resulted 
in reduced effector and memory cell numbers. Initial attempts to block MHC-II in 
WT hosts were unsuccessful likely due to the abundance of MHC-II expression 
during IAV infection (data not shown). I therefore sought to establish a model with 
limited MHC-II expression that still promoted normal memory CD4 T cell formation. 
To this end, I compared CD4 memory T cell formation in B6 mice to CD11cTg.H2-
Ab1 /  (CD11cTg) mice. CD11cTg mice are MHC-II knockout mice with a transgene 
that expresses MHC-II under the CD11c promoter. Therefore, these mice only 
express MHC-II on CD11c+ cells (Figure 3.7A).  
To test if memory formation occurred normally in these mice, I transferred 
naïve OT-II cells into B6 or CD11cTg mice and infected with PR8-OVAII. Similar  
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Figure 3.6. 14 dpi effectors no longer require Ag to form memory. 
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Figure 3.6. 14 dpi effectors no longer require Ag to form memory. 
 
(A-B) 5x105 naïve OT-II.Nur77GFP.Thy1.1+/  were transferred to B6 hosts. Hosts 
were infected with PR8-OVAII. On the same day, groups of B6 mice were either 
infected with PR8-OVAII or PR8. On 14 dpi, donor OT-II cells were isolated from 
the spleen and DLN of infected mice. 2x106 14 dpi effectors were transferred to 
the PR8-OVAII, PR8, or uninfected hosts. (A) Experimental schematic. (B) Cell 
recovery at 7 dpt. (C) Comparison of CFSE dilution between 6 dpi effectors and 
14 dpi effectors 3 dpt into PR8-OVAII-infected, PR8-uninfected, or uninfected 
second hosts. Data is representative, n=3-4 each, 3 experiments, mean ± SD. 
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numbers of effectors were generated at 9 dpi and similar numbers of memory cells 
were generated in all organs at 28 dpi (Figure 3.7B). Memory cells generated in 
CD11cTg mice appeared to be functional, as a similar percentage produced IFNg 
and IL-2 following peptide re-stimulation ex vivo (Figure 3.7C). This finding 
indicates that MHC-II on the CD11c+ compartment is sufficient for memory 
formation. 
 Given that memory formation occurred normally in the CD11cTg mice, I 
used them as hosts for a MHC-II blocking experiment. I transferred naïve OT-II 
cells into CD11cTg hosts and infected with PR8-OVAII. Then I treated the mice 
with anti-MHC-II Ab (clone M5114) on day 4-7 of infection (Figure 3.8A). At 7 dpi, 
most MHC-II expression was significantly blocked especially in the SLO (Figure 
3.8B). Only a modest reduction was seen in the lung (Figure 3.8B). At 7 dpi, the 
number of donor cells was significantly reduced in all organs when MHC-II was 
blocked during the effector phase (Figure 3.8C). This is consistent with the 
immediate contraction seen in 6 dpi effectors transferred to hosts without Ag 
(Figure 3.5E). Importantly, priming did not appear to be affected as the donor cells 
in both mice produced similar levels of IFNg upon ex vivo re-stimulation (Figure 
3.8D). These findings suggest that responding CD4 effector T cells require Ag 
recognition during the effector phase for their full expansion. 
 At a memory time point (27-28 dpi), there was a significant reduction in 
memory cell formation in the lung and the spleen, however no reduction was seen 
in the DLN (Figure 3.8E). Interestingly, the memory cells formed in the DLN in the  
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Figure 3.7. MHC-II on CD11c+ cells is sufficient for CD4 memory T cell 
formation. 
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Figure 3.7. MHC-II on CD11c+ cells is sufficient for CD4 memory T cell 
formation. 
 
(A) Representative flow cytometry plot of MHC-II expression on CD11c+ and 
CD11c  cells in either WT B6 or CD11cTg mice in the spleen. (B-C) OT-II.Thy1.1+/  
naïve cells were transferred to WT or CD11cTg mice followed by infection with a 
sublethal dose of PR8-OVAII. (B) Donor cell recovery at 9 and 28 dpi in WT or 
CD11cTg mice in the lung, spleen, and DLN. (C) Representative flow cytometry 
plots showing IFNg and IL-2 production of donor cells in the spleen following 4 
hours of re-stimulation with aCD3 and aCD28 Ab at 28 dpi. Data is representative 
of 2 independent experiments, n=3-5 each, mean ± SEM. 
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Figure 3.8. Late MHC-II is required for CD4 memory T cell formation. 
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Figure 3.8. Late MHC-II is required for CD4 memory T cell formation. 
 
(A-F) 5x104 naïve OT-II.Thy1.1+/  cells were transferred to CD11cTg mice followed 
by sublethal PR8-OVAII infection. Mice were then treated with aMHC-II Ab (M5114) 
at 1mg/mouse/day administered via i.v. injection. (A) Experimental schematic. (B) 
Representative flow cytometry plots showing MHC-II staining in the lung, spleen, 
and DLN of CD11c+ cells in treated and untreated mice compared to CD11c  cells. 
(C) Donor cell recovery at 7 dpi. (D) IFNg production of donor cells at 7 dpi following 
4 hours of re-stimulation with aCD3 and aCD28 Ab. (E) Donor cell recovery at 27-
28 dpi. (F) CD127 expression of donor cells in the DLN of treated and untreated 
mice at 28 dpi. (B, D, F) Representative data of 2 independent experiments, n=3-
5 each, mean ± SD. (C, E) Pooled data, 2 experiments, n=3-5 each, mean ± SD. 
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absence of late Ag had reduced CD127 expression. This suggests that they may 
not be as fit to receive the IL-7 signals required for long term survival. The fact that 
no impact was seen in the DLN is surprising given that large effects were seen in 
all three organs in the transfer model. It is possible that MHC-II blocking was not 
complete enough to effect memory formation in the DLN. Alternatively, since 
CD11cTg mice have a deficiency in endogenous CD4 T cells, survival niches may 
be more available to donor CD4 T cells resulting in less competition and therefore 
less stringency in the requirements for memory formation.  However, the fact that 
blocking MHC-II during the effector phase largely mimicked the results of the 
transfer experiments provides evidence that the transfer model largely replicates 
what occurs during the course of the endogenous CD4 T cell response to IAV. 
 
Late Ag is Required for Full Expansion. 
Some studies suggest that effector CD4 T cell division is programmed by 
initial Ag encounter (247, 248), while others suggest that CD4 T cells do not 
undergo such “autopilot” proliferation after 2 days of stimulation during priming 
(249), but it remains unclear if they acquire this ability later during infection. To 
determine if division past 6 dpi depends on Ag recognition, I labeled isolated 6 dpi 
effectors with CFSE, transferred to infection-matched PR8-OVAII-infected, PR8-
infected or uninfected hosts (as in Figure 3.5A) and assayed dilution of CFSE at 3 
dpt. Only donor cells in hosts with Ag divided more than once (Figure 3.9A). To 
determine if this proliferation was an artifact of the transfer system, I used Ki67 
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staining to compare the proliferation of donor OT-II cells to that of endogenous IAb-
NP311 325-specific host cells in PR8-OVAII-infected hosts. I found that at 2 dpt there 
was a similar percentage of proliferating donor and hosts cells, and by 8 dpt neither 
were undergoing division, a pattern seen in the lung, spleen, and DLN (Figure 
3.9B, 3.9C).  Thus, division after 6 dpi is Ag-dependent, short-lived, and followed 
by the transition to non-dividing cells within a week. This also illustrates that the 
kinetics of proliferation of the transferred donor cells mimics that of the 
endogenous host CD4 T cell response to live IAV. 
Some have reported that late Ag promotes increased effector expansion but 
leads to exacerbated contraction, resulting in fewer or similar numbers of long-
lived memory cells (139, 263). To determine if the increased number of donor cells 
in the PR8-OVAII-infected hosts was the result of an extended expansion of short-
lived effectors, I assayed the size and phenotype of donor cells 2 and 8 dpt (Figure 
3.9D, 3.9E). At 2 dpt, the donor cells where large in size (Figure 3.5D), with a high 
level expression of effector markers ICOS and PD-1 (Figure 3.5E), but by 8 dpt 
they were small (Figure 3.9D) and had downregulated ICOS and PD-1 (Figure 
3.9E). Thus, by 8 dpt donor cells no longer had an effector phenotype and had 
mostly transitioned to resting cells. 
 
Short-term Ag Presentation at 6-8 dpi is Sufficient to Restore CD4 T cell 
Responses to IAV.  
Given that re-encounter with Ag was required at 6 dpi but not 14 dpi, I tested  
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Figure 3.9. Late Ag is required for full proliferation.  
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Figure 3.9. Late antigen is required for full proliferation.  
 
(A) 6 dpi effectors were isolated, stained with CFSE, and transferred to kinetically 
matched PR8-OVAII or PR8-infected or uninfected hosts as in Figure 3.5A. CFSE 
dilution was determined 3 dpt in the spleen, similar results seen in the lung. (B-E) 
Same experimental approach as in Figure 3.5A. Ki67 expression of donor OT-II 
and NP311 325 tetramer positive host cells was determined at indicated time points 
following donor cell transfer. (B) Representative flow cytometry plot shown of the 
spleen. (C) Quantification of Ki67 staining in the lung, spleen, and DLN at 2 dpt (8 
dpi) and 8 dpt (13 dpi). (D) Forward scatter and (E) ICOS and PD-1 expression of 
donor OT-II transferred to PR8-OVAII infected hosts either 2 or 8 dpt. 
Representative data, n=3-5 each, 2 independent experiments, mean ± SD. 
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whether a short exposure of donor cells to Ag was sufficient to induce memory 
formation. I transferred 6 dpi OT-II donor cells to PR8-infected mice and tested if 
intravenously injected bone marrow-derived dendritic cells pulsed with OVAII-
peptide (DC-OVAII) would be sufficient to restore memory formation. I found that 
these DC present Ag for no longer than 2 days after transfer in vivo by tracking 
their ability to induce proliferation of naïve OT-II cells (Figure 3.10A, 3.10B). 
Strikingly, the donor cells transferred to PR8-infected hosts that received DC-OVAII 
were recovered at similar levels as those transferred to PR8-OVAII-infected hosts 
out to 14 dpt (Figure 3.11A-3.11C). The kinetics of the donor cell response was 
very similar in the spleen and lung, with a slight reduction in the DLN of donor cells 
transferred to PR8-infected mice with DC-OVAII (Figure 3.11C).  
To examine if memory phenotype was altered when late Ag was provided 
by DC-OVAII compared to virally produced Ag, I measured CD127, CXCR3 and 
TCF-1 expression. In the lung and spleen, both CD127 and CXCR3 expression 
were similar between cells in the PR8-OVAII host and those in the PR8 host with 
DC-OVAII (Figure 3.11D, 3.11E). However, both markers were increased in the 
memory cells formed in the DLN of the PR8-infected host with DC-OVAII. Since 
fewer memory cells formed in these mice, it could be that the only cells that were 
able to survive were those with much higher memory cell markers. TCF-1, a 
transcription factor that has been shown to be required for memory cell formation 
in CD8 T cells (312), was similar between the two groups in all organs (Figure 
3.11F). This indicates that encounter with cognate Ag for 48 hours or less, starting  
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Figure 3.10. Transferred OVAII-DC only present Ag for 2 days in vivo. 
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Figure 3.10. Transferred OVAII-DC only present Ag for 2 days in vivo. 
 
(A) Experimental schematic. 0.5x105 OVAII-pulsed BMDC were transferred to 
uninfected hosts.  To determine how long BMDC present the OVAII-peptide, naïve 
OT-II cells were CFSE labelled and transferred either at the same time as OVAII-
pulsed BMDC (time 0), 2 days after OVAII-pulsed BMDC, or in the absence of 
OVAII-pulsed BMDC. (B) Activation and proliferation were determined by analyzing 
CD44 expression and CFSE dilution by flow cytometry. Data is representative of 
an experiment with n=5.  
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Figure 3.11. Short-term Ag is sufficient to restore the CD4 T cell response. 
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Figure 3.11. Short-term Ag is sufficient to restore the CD4 T cell response. 
 
(A-F) 5x105 naïve OT-II.Nur77GFP.Thy1.1+/  were transferred to B6 mice. Mice were 
infected with PR8-OVAII. At 6 dpi, donor OT-II cells were isolated as described in 
Figure 3.5A, and transferred to kinetically-matched PR8-OVAII or PR8 infected 
hosts along with 0.5x106 BMDCs either pulsed with 10µM OVAII-peptide or not. (A) 
Experimental schematic. (B) Donor cell recovery at 7 dpt. (C) Kinetics of cell 
recovery in the lung, spleen, and DLN. (D) CD127 (E) CXCR3 and (F) TCF-1 
expression at 14 dpt (20 dpi). Data is representative of 2 individual experiments, 
n=3-5 each. Mean ± SD. 
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at 6 dpi, was sufficient to prevent excessive contraction and promote memory 
formation. 
 
Short-term Ag Presentation at 6-8 dpi in the Absence of Viral Infection is 
Sufficient to Restore CD4 T cell Responses to IAV. 
To determine if viral infection itself is important in promoting memory 
formation, I tested whether adding DC-OVAII would similarly increase memory 
formation in uninfected hosts. 6 dpi effectors were transferred to PR8-infected 
hosts with DC-OVAII, uninfected hosts with DC-OVAII, or uninfected hosts with 
unpulsed DC (Figure 3.12A). Strikingly, DC-OVAII strongly promoted donor 
recovery to a similar extent in PR8-infected and uninfected hosts (Figure 3.12B). 
Since Ag presentation only lasts for 2 days in vivo, donor cells appeared to have 
a resting phenotype by 7 dpt, having downregulated effector molecules PD-1 and 
ICOS compared to 6 dpi effectors (Figure 3.12C). Additionally, CD127 and CXCR3 
expression was similar between donor cells in PR8-infected or uninfected hosts 
that received DC-OVAII (Figure 3.12D). TCF-1 was also similar between donor 
cells formed with and without viral infection (Figure 3.12E). Since the TCF-1 
expression appeared to be lower in the lung than the SLO, I included a comparison 
of host CD4+CD44h CD62Lh  memory cells to see if this level of TCF-1 expression 
was normal in lung memory cells. I found that host memory cells expressed similar 
levels of TCF-1 expression in both the lung and the spleen as did the donor OT-II 
cells (Figure 3.12E). This suggests that donor cells are phenotypically memory- 
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Figure 3.12. Short-term Ag can restore the CD4 T cell response in the 
absence of viral infection. 
  
PR8 + DC OVAII 
No v rus + DC OVAII 
No v rus + DC 
 
 
10
6 
10
5 
10
4 
10
3 
10
2 
Lung Sp een 
** 
ns 
** * 
 d
on
or
 O
T
II 
ce
s 
pe
r o
rg
an
 7 dpt 
 
 
1000 
800 
400 
200 
0 
600 
M
FI
 
PD 1 
 
0
0
 
10000 
8000 
4000 
200  
 
6000 
M
FI
 
ICOS 
6 dp  OT II 
OT II 7 dpt  
PR8 host 
OT II 7 dpt 
No v rus host  
Naïve OT II.Thy1.1 
Infect PR8 OVAII 
6 dp    
OT II  
No 
V rus 
PR8 
+ DC OVAII 
6 dp  
A 
No V rus 
+ DC OVAII 
400 
300 
100 
0 
200 MF
I 
CD127 
5000 
4000 
2000 
1000 
0 
3000 
M
FI
 
CXCR3 
Lung Sp een Lung Sp een 
Lung: TCF 1 
80 
60 
20 
0 
40 
%
 T
C
F
1h
i o
f O
T
II 
Lung Sp een 
100 
50 
0 % 
TC
F
1h
i o
f O
T
II 
Sp een: TCF 1 
Lung Sp een 
OT II PR8 host 
OT II No v rus host  
6 dp  OT II 
OT II 7 dpt PR8 host 
OT II 7 dpt No v rus host  
Host CD44
hi 
CD62L
hi 
B 
C 
D 
E 
	 92	
Figure 3.12. Short-term Ag can restore the CD4 T cell response in the 
absence of viral infection. 
 
(A-E) 6 dpi OT-II effectors were isolated from PR8-OVAII-infected mice and 
transferred to second hosts that were either infected with PR8 (6 dpi) or uninfected, 
along with BMDC that were pulsed with OVAII-peptide or not. (A) Experimental 
schematic. (B) Cell recovery was assayed 7 dpt. (C) PD-1 and ICOS expression 
of donor cells at 7 dpt in the spleen compared to 6 dpi OT-II effectors. (D) CD127 
and CXCR3 expression of donor cells in the spleen at 7 dpt. (E) TCF-1 expression 
of donor cells compared to host memory cells (CD44h CD62Lh ) and 6 dpi OT-II 
effectors. All data is representative, n=3-5 each, 2-3 experiments, mean ± SD. 
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like by 7 dpt. Since it is unclear to what extent TCF-1 is required for tissue resident 
memory formation, it may be that memory cells in the lung do not express as much 
TCF-1 as those in the SLO. These data, combined with Figure 3.5, in which there 
was no difference in memory formation following transfer of 6 dpi effectors into 
PR8-infected and uninfected hosts, suggests that at this time Ag-independent 
aspects of infection, such as induction of lung inflammatory cytokines, have no 
discernable impact on memory formation. However, the DC I used were activated, 
so infection-induced viral-sensing pathways may be needed to activate in situ 
APC.  
Although the use of DC-OVAII to mimic the late Ag presentation of a viral 
infection appeared to replicate the CD4 T cell response well, it is possible that 
providing activated DC pulsed with cognate peptide might provide a non-
physiological level of stimulation. To test this, I transferred 6 dpi effectors into 
infection matched PR8-OVAII-infected hosts, PR8-infected hosts with DC-OVAII, or 
uninfected hosts with DC-OVAII and measured cell recovery at 2 dpt. If the DC-
OVAII provided a much larger boost of Ag than did viral infection, one would expect 
that the donor cells in the hosts with DC-OVAII would be present at much greater 
numbers than the PR8-OVAII host. However, I found that there were similar 
numbers of donor cells present in all three hosts in the lung, spleen, and DLN 
indicating that DC-OVAII reliably replicate Ag presentation during viral infection 
(Figure 3.13). 
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Figure 3.13. DC-OVAII induces similar effector expansion as PR8-OVAII 
infection. 
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Figure 3.13. DC-OVAII induces similar effector expansion as PR8-OVAII 
infection. 
 
6 dpi effectors were transferred to PR8-OVAII-infected, PR8-infected hosts + DC-
OVAII, or uninfected hosts + DC-OVAII. Lung, spleen, and DLN were harvested at 
2 dpt. OT-II cell numbers are shown. Data is pooled from 2 independent 
experiments, n=7-8. Mean ± SD. 
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Short-term Ag is Sufficient to Restore Canonical Memory Formation. 
I further examined if memory formation occurred normally when late Ag was 
provided by short-lived DC-OVAII. I directly compared OT-II memory generated 
when naïve cells were transferred on day 0 and left in the same initial host (No Eff. 
Trans.) or when 6 dpi OT-II effectors were isolated and transferred (Eff. Trans.) to 
kinetically-matched PR8-OVAII-infected, PR8-infected with DC-OVAII, or 
uninfected hosts with DC-OVAII. To highlight the changes that distinguish memory 
cells from effectors, I included 6 dpi OT-II effectors for comparison.  
One functionally important characteristic of memory cells is their ability to 
produce multiple cytokines upon re-stimulation (2). I found that the memory cells 
generated following transfer (either to hosts with virally produced Ag or with short-
lived Ag provided by DC-OVAII) had regained the ability to produce multiple 
cytokines to a similar extent as those generated without transfer (Figure 3.14A, 
3.13B). Additionally, memory cells generated both with and without transfer had 
upregulated the critical memory marker CD127 that is necessary for their 
persistence (Figure 3.14C). Interestingly, when comparing memory cells 
generated in PR8-infected or uninfected hosts with late transfer of DC-OVAII, there 
was a decrease in CD127 expression in the uninfected hosts (Figure 3.14C). This 
suggests that although systemic virus-induced inflammatory cytokines may not be 
needed for memory cell numbers, function, or subset differentiation, it may be that 
virus-induced inflammatory cytokines are required for full CD127 upregulation.  
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Figure 3.14. Short-term Ag is sufficient to restore canonical memory 
formation. 
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Figure 3.14. Short-term Ag is sufficient to restore canonical memory 
formation. 
 
(A-C) Comparison of memory cells generated following transfer of naïve OT-II at 
day 0, or transfer of 6 dpi OT-II effectors into PR8-OVAII-infected, PR8-infected 
with DC-OVAII, or uninfected hosts with DC-OVAII. Memory cells harvested 14 dpt 
(20 dpi) were compared to 6 dpi effectors generated in vivo. (A) Representative 
flow cytometry plots showing intracellular cytokine staining of IFNg and TNFa 
following 4 hours of PMA + Ionomycin stimulation in memory or 6 dpi effector OT-
II cells. (B) Percentage of IFNg+TNFa+, IFNg+TNFa+IL-2+ producing cells in 
memory or effector OT-II populations in the spleen. (C) CD127 MFI of effectors 
and all memory groups in the lung, spleen, and DLN. Data is pooled, n=6-8, 2 
experiments, mean ± SD. 
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However, the equivalent recovery of memory cells argues that DC-OVAII exposure 
induced sufficient levels of CD127 for persistence.  
I next examined CD4 memory subset differentiation. The tissue resident 
memory (Trm) population identified by CD69 expression (5, 143) in the lung was 
similar with and without transfer (Figure 3.15A). IFNg production, an indicator of 
Th1 differentiation (313, 314), was also produced to a similar extent in all memory 
groups (Figure 3.15A). CXCR5 has been shown to mark a memory subset that is 
thought to be T follicular helper (Tfh) or central memory (Tcm)-like (148, 149). 
CXCR5 expression was also similar among all memory groups (Figure 3.15B). 
Although there appeared to be a slight increase in CXCR5 expression in groups 
receiving DC-OVAII in the spleen, this pattern was not found in the DLN. Therefore, 
the limited Ag provided by DC-OVAII at 6 dpi appears to be sufficient to generate 
canonical memory formation. 
 
Late Ag Promotes Survival of Responding CD4 T cells. 
After viral clearance, most effector T cells undergo apoptosis leading to 
contraction, while a cohort survives to become memory. This suggests that 
avoiding apoptosis is a key step in the transition to memory. I therefore propose 
that a cohort of effector CD4 T cells recognize Ag/APC which drives them to make 
and respond to IL-2, which drives their survival and supports their transition to 
memory (1). I evaluated several components of this hypothesis. 
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Figure 3.15. Short-term Ag is sufficient to restore memory differentiation. 
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Figure 3.15. Short-term Ag is sufficient to restore memory differentiation. 
 
 
(A, B) Comparison of memory cells generated following transfer of naïve OT-II at 
day 0, or transfer of 6 dpi OT-II effectors into PR8-OVAII-infected, PR8-infected 
with DC-OVAII, or uninfected hosts with DC-OVAII. Memory cells harvested 14 dpt 
(20 dpi) were compared to 6 dpi effectors generated in vivo. (A) Quantification of 
Trm via CD69 expression (Lung), Th1 via IFNg production (Spleen). (B) 
Quantification of Tfh/Tcm via CXCR5 expression of memory or effector OT-II cells 
in the lung, spleen, and DLN. Data is pooled, n=6-8, 2 experiments, mean ± SD.  
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To test if Ag recognition at the checkpoint promoted enhanced survival of 
effector CD4 T cells, I transferred naive OT-II.Nur77GFP cells to hosts and infected 
with PR8-OVAII. At 7 dpi, donors that had seen Ag during the first 1-2 days of the 
checkpoint are GFP+ while those that did not, are GFP . I analyzed donor CD4 T 
cells from the lung, spleen, and DLN directly ex vivo, gating on GFP+ and GFP  
cells. To detect cell death directly ex vivo I measured 7-Aminoactinomycin D (7-
AAD) staining (Figure 3.16). In each organ, 7-AAD staining was significantly 
greater in GFP  cells than in GFP+ cells, indicating that more effector cells that 
recognized Ag between 5-6 dpi survived than those that did not recently encounter 
Ag.  
To further dissect the mechanisms involved in this survival, I developed an 
in vivo to in vitro model to better control the signals that the effectors receive. I 
isolated 6 dpi OT-II effectors and co-cultured them with T-depleted splenocytes 
isolated from PR8-infected mice, a physiologically relevant APC, either with or 
without OVAII peptide. To mimic the short-term Ag presentation that occurs in vivo, 
I irradiated the APC, ensuring Ag presentation was restricted to the first 2 days of 
culture (Figure 3.17A) (245). As I found in vivo, in this in vitro model when I 
measured 7-AAD staining after 2 days in culture, I found that the cells that did not 
receive late Ag stimulation had significantly increased 7-AAD staining compared 
to the cells that received late Ag stimulation (Figure 3.17B).  
To test if this was true of polyclonal 6 dpi IAV-specific CD4 T cells, I modified 
the in vivo to in vitro model by isolating total CD4 T cells at 6 dpi and culturing with  
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Figure 3.16. Recent Ag encounter correlates with reduced cell death in vivo. 
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Figure 3.16. Recent Ag encounter correlates with reduced cell death in vivo. 
 
OT-II.Nur77GFP.Thy1.1+/  naïve T cells were transferred to B6 mice followed by 
infection with PR8-OVAII. Lung, spleen, and DLN were harvested 7 dpi. Left: 
Representative plot of GFP+ vs. GFP  OT-II.Nur77GFP cells.  Right: Quantification 
of 7-AAD+ of GFP+ vs. GFP  OT-II Nur77GFP cells on 7 dpi. Representative data, 2 
experiments, n=3-5 each, mean ± SD. 
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Figure 3.17. Short-term Ag at 6 dpi promotes cell survival. 
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Figure 3.17. Short-term Ag at 6 dpi promotes cell survival. 
 
(A,B) 5x105 naïve OT-II.Thy1.1+/  were transferred to B6 mice followed by infection 
with PR8-OVAII. At 6 dpi, OT-II effectors were isolated and co-cultured with 
irradiated Thy-depleted splenocytes from infection-matched PR8-infected mice 
either with or without OVAII-peptide. (A) Experimental schematic. (B) 7-AAD 
staining of OT-II cells after 2 days in culture. Left: Representative staining. Right: 
Quantification of 7-AAD+ cells. All data is representative, n=3-4 each, 3 
experiments, mean ± SD. 
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or without NP311 325 peptide using in vitro-activated Thy-depleted splenocytes as 
APC (Figure 3.18A). After 6 days of culture, I found that polyclonal effectors that 
were exposed to late Ag were present at much higher levels than those that were 
not (Figure 3.18B, 3.18C). Similar to OT-II cells, when I measured 7-AAD staining, 
I found that cells that were cultured in the absence of late Ag had much greater 
cell death compared to those that were cultured with late Ag (Figure 3.18D). 
Interestingly, the MFI of the tetramer bound to cells that received late Ag was much 
higher than that of the cells that did not receive late Ag (Figure 3.18E). Since 
tetramer binding can be used to measure TCR affinity (315), this suggests that the 
presence of late Ag may have introduced some selection pressure favoring clones 
that recognized IAb-NP311 325 with greater avidity for enhanced survival (Figure 
3.18E). However, I did not measure TCR expression which could also explain the 
differences in tetramer MFI. Although, after 6 days of culture, all cells are quiescent 
and are unlikely to have large differences in their TCR expression. Given that 
memory cells have increased functional avidity compared to effectors (304), it is 
an intriguing hypothesis that this late Ag might promote memory formation of 
effectors with high affinities. 
To determine how Ag dose during this late time point impacted survival, I 
titrated the concentration of OVAII peptide used to pulse in vitro-activated Thy-
depleted splenocytes and measured cell recovery after 6 days of culture. Cell 
recovery appeared to plateau around 0.01µM of peptide (Figure 3.19). Given that 
naïve cells are generally stimulated with 10µM, 6 dpi effectors are more sensitive  
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Figure 3.18. Late Ag promotes survival of polyclonal CD4 T cells. 
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Figure 3.18. Late Ag promotes survival of polyclonal CD4 T cells. 
 
(A-E) B6 were infected with a sublethal dose of PR8. At 6 dpi total CD4 T cells 
were isolated and co-cultured with irradiated APC (activated with LPS and dextran 
sulfate) with or without NP311 325 peptide and cultured for 6 days. (A) Experimental 
schematic. (B) Representative flow cytometry plots of IAb-NP311 325 tetramer 
staining of CD4+CD44h  cells. (C) Cell recovery of IAb-NP311 325 tetramer positive 
cells. (D) Percentage 7-AAD+ of NP311 325-specific cells. (E) Tetramer MFI of IAb-
NP311 325 tetramer positive cells with and without late Ag. Data is representative of 
2 experiments, n=3 each, mean ± SD. 
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Figure 3.19. Increased cell recovery with increased Ag concentration.  
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Figure 3.19. Increased cell recovery with increased Ag concentration.  
 
6 dpi OT-II.Thy1.1+/  effectors were isolated as in (Figure 3.17A) and cultured with 
irradiated, activated APC that were previously pulsed with varying concentrations 
of OVAII peptide for 1 hour at 37 degrees Celsius. Cell recovery was measured by 
flow cytometry after 6 days of culture. Data is from an experiment with n=3, mean 
± SD. 
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to lower doses of Ag. Additionally, it did not seem that higher concentrations of Ag 
were deleterious at this late time point (Figure 3.19). 
Next I tested if the pro-survival effects of late Ag were sustained in vitro. 
The differences in cell recovery between cells that received late Ag for just the first 
2 days of culture and those that had not were maintained out to 14 days of culture 
in both OT-II and polyclonal cells (Figure 3.20A, 3.20C). Additionally, although 
CD127 expression started out fairly similar between the two populations, the cells 
that received late Ag, for just the first 2 days of culture, gradually upregulated 
CD127, while those that did not receive late Ag failed to do so (Figure 3.20B, 
3.20D). The differences in CD127 expression were most apparent after 14 days of 
culture, consistent with the idea that unlike CD8 T cells, primary CD4 T cells 
upregulate CD127 as they transition to memory (205). Thus, instead of re-
encounter with Ag inducing widespread cell death, it promoted survival of in vivo-
generated 6 dpi effector T cells. 
 
Late Ag Promotes Survival of Responding CD4 T cells by Reducing Bim 
Expression. 
To determine what might be responsible for the survival of cells exposed to 
late Ag, I performed a microarray experiment on 6 dpi effectors cultured for 2 days 
either with aCD3 and aCD28 or without and compared the gene expression of 
those two groups with that of the population of 6 dpi effectors I plated. A few 
apoptosis-related genes were upregulated above the 2-fold cutoff in the media  
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Figure 3.20. Short-term Ag promotes long term survival and upregulation of 
CD127 in OT-II and polyclonal CD4 T cells. 
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Figure 3.20. Short-term Ag promotes long term survival and upregulation of 
CD127 in OT-II and polyclonal CD4 T cells. 
 
(A-B) 6 dpi OT-II.Thy1.1+/  effectors were isolated and co-cultured with irradiated 
APC with or without OVAII peptide as in (Figure 3.17A). Cell recovery (A) and 
CD127 expression (B) were measured after 1, 6, and 14 days of culture. (C-D) 
Total CD4 T cells were isolated at 6 dpi and co-cultured with irradiated APC with 
or without NP311 325 peptide as in (Figure 3.18A). Cell recovery (C) and CD127 
expression (D) were measured after 2, 6, and 14 days of culture. Data is 
representative of 2-3 experiments, n=3 each, mean ± SD. 
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alone group (Figure 3.21A). One of the genes that came up was Bcl2l11 (which 
encodes Bim), a pro-apoptotic protein known to mediate cell death during T cell 
contraction (171, 190). When I measured Bim protein expression following 2 days 
of culture with or without late Ag/APC, I found that cells cultured without Ag had 
significantly increased Bim expression (Figure 3.21B). 
I next tested if the reduced level of Bim seen in the Ag-exposed effectors 
was responsible for their increased survival. I co-transferred WT GFP Bcl2l11+/+ or 
Bcl2l11+/  [which express half the WT levels of Bim (187)] OT-II cells mixed at a 1:1 
ratio into B6.Thy1.1+/  mice and infected with PR8-OVAII. I harvested total effector 
CD4 T cells at 6 dpi and stimulated them ex vivo with APC with or without OVAII-
peptide (Figure 3.21C). Bcl2l11+/  OT-II and WT OT-II were still present at similar 
ratios at 6 dpi, indicating that Bcl2l11+/  OT-II were expanded normally (Figure 
3.21D). Additionally, both WT OT-II and Bcl2l11+/  OT-II produced similar levels of 
IFNg upon ex vivo re-stimulation at 6 dpi, suggesting that Bcl2l11+/  OT-II were 
activated and functional (Figure 3.21E).  
Next I measured cell recovery after 14 days of culture. I found that when no 
Ag was present in vitro, the Bcl2l11+/  OT-II cells survived much better than WT 
OT-II cells (Figure 3.21F), implicating high levels of Bim in the death and 
contraction of 6 dpi effectors in the absence of Ag. In contrast, in the presence of 
Ag, the Bcl2l11+/  OT-II and WT OT-II cells survived comparably (Figure 3.21F), 
consistent with the hypothesis that Ag acts to counteract apoptosis by causing Bim 
reduction. Indeed, in the absence of Ag, the Bcl2l11+/  OT-II cells expressed less  
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Figure 3.21. Survival following late Ag stimulation is mediated by Bim 
reduction.  
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Figure 3.21. Survival following late Ag stimulation is mediated by Bim 
reduction.  
 
(A) 6 dpi OT-II.Thy1.1+/  effectors were isolated as in (Figure 3.17A), and cultured 
with 1µg/ml aCD3 and 5µg/ml aCD28 or in media alone for 2 days. Live OT-
II.Thy1.1+/  cells were then sorted and RNA was isolated from the media alone 
group, the TCR stimulated group, and sorted 6 dpi effectors. Microarray analysis 
was then performed on each sample. Shown are the apoptosis-related genes that 
were increased over 2-fold in the media alone group over both the TCR and 6 dpi 
effector groups. (B) 6 dpi OT-II.Thy1.1+/  effectors were isolated and co-cultured 
with irradiated APC with or without OVAII peptide as in (Figure 3.17A). After 2 days 
in culture, Bim protein expression was measured by flow cytometry. (C-G) WT GFP 
or Bcl2l11+/  OT-II cells were mixed at a 1:1 ratio and co-transferred into 
B6.Thy1.1+/  mice followed by infection with PR8-OVAII. 6 dpi effectors were 
isolated and cultured with APC with and without OVAII peptide. (C) Experimental 
schematic. (D) Representative flow cytometry plot showing the percentage of WT 
and Bcl2l11+/  OT-II cells at 6 dpi, gated on donor cells. (E) IFNg production of 
donor WT and Bcl2l11+/  OT-II in the spleen at 6 dpi after 4 hours of aCD3 and 
aCD28 stimulation. (F) Relative recovery of WT or Bcl2l11+/  OT-II cells after 14 
days of culture. (G) Bim expression of WT and Bcl2l11+/  OT-II after 2 days of 
culture. (A) Data is pooled from 2 independent experiments. (B-G) Data is 
representative of 3 experiments, n=3 each, mean ± SD.  
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Bim than WT, but with Ag, Bim levels were similar (Figure 3.21G). This supports 
the hypothesis that Ag recognition by effectors at the checkpoint acts in part 
through reduction of Bim expression, which prevents apoptosis and promotes 
survival. 
 
IL-2 is Required for the Pro-survival Effects of Late Ag. 
Since our previous studies found that autocrine IL-2 was required for CD4 
effector survival (1), I tested whether Ag stimulation of 6 dpi effectors ex vivo would 
promote IL-2 production and if that IL-2 was necessary for enhanced survival. 
Indeed, the ex vivo effector CD4 T cells produced IL-2 only when cultured with 
Ag/APC (Figure 3.22A). I cultured 6 dpi effectors with APC, Ag/APC, or Ag/APC 
plus Ab specific for both CD25 (IL-2Ra) and CD122 (IL-2Rb) to block IL-2 function. 
The exposure to Ag/APC enhanced donor cell recovery after 6 days, and blocking 
IL-2 signaling reduced that recovery (Figure 3.22B). Notably, blocking IL-2 only 
slightly inhibited Ag/APC-induced proliferation (Figure 3.22C), but dramatically 
increased cell death as measured by 7-AAD staining (Figure 3.22D).    
Next, I stained Bim after 2 days of culture to see if IL-2 aided in the Bim 
reduction seen in groups receiving late Ag. I found that blocking IL-2 did 
significantly increase Bim expression (Figure 3.22E). Finally, given the role of IL-2 
signaling in promoting CD127 expression (1, 206), I measured CD127 expression 
after 14 days of culture. As expected, blocking IL-2 significantly reduced CD127 
expression following late Ag recognition (Figure 3.22F). Thus, in vitro Ag/APC 
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stimulation of 6 dpi effectors induces IL-2 production that prevents apoptosis and 
enhances the survival necessary for memory formation. Partial effects seen on cell 
recovery (Figure 3.22B), cell proliferation (Figure 3.22C), and upregulation of 
CD127 (Figure 3.22F) imply that factors beyond IL-2 also play a role in the effects 
of Ag seen at the late checkpoint. 
To determine if polyclonal cells are also dependent on IL-2 signaling for 
survival, I used the same experimental setup as in Figure 3.22 using total CD4 T 
cells isolated at 6 dpi. I found significantly reduced cell recovery after 6 days of 
culture in cells receiving late Ag where IL-2 signaling was blocked (Figure 3.23A, 
3.23B). As I saw with OT-II cells, cell recovery was not completely inhibited when 
IL-2 was blocked suggesting that other factors likely have a role in promoting 
survival at this late time point. Proliferation of polyclonal cells did seem to be a bit 
more impacted when IL-2 was blocked than I saw with OT-II cells (Figure 3.23C). 
Interestingly, in the absence of late Ag, polyclonal cells underwent significantly 
more proliferation than do OT-II cells in the absence of late Ag. Given that the 
polyclonal cells identified by tetramer are composed of clones of varying affinities 
they are likely not as synced as transgenic cells. Therefore, it is possible that some 
clones may be still undergoing some “autopilot” proliferation. Additionally, blocking 
IL-2 led to increased cell death, though not as robust as in OT-II cells (Figure 
3.23D).  
When I stained for Bim after 2 days of culture, I found that while late Ag 
stimulation did result in a reduction in Bim, the level of Bim expression was not  
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Figure 3.22. IL-2 is required for the pro-survival effects of late Ag.  
 
(A) 6 dpi OT-II.Thy1.1+/  effectors were isolated and co-cultured with irradiated 
APC with or without OVAII peptide as in (Figure 3.17A). (A) After 4 hours of culture 
IL-2 production was assayed by intracellular staining. (B-F) 6 dpi effectors were 
co-cultured with APC without Ag, with Ag, or with Ag plus aCD25 + aCD122. Cells 
were stained with CTV. (B) Cell recovery was determined after 6 days of culture. 
(C) Dilution of CTV after 2 days of culture. (D) 7-AAD+ after 14 days of culture. (E) 
Bim expression after 2 days of culture. (F) CD127 expression after 14 days of 
culture. All data is representative, n=3-4 each, 3 experiments, mean ± SD. 
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affected by blocking IL-2 (Figure 3.23E). Blocking IL-2, however, did substantially 
reduce CD127 expression after 14 days of culture (Figure 3.23F). This was in 
contrast to the OT-II results (Figure 3.22E) suggesting that in the more 
heterogeneous polyclonal population IL-2 may have less of a dominant role. The 
fact that blocking IL-2 did not completely diminish the increased cell survival 
following late Ag also suggests that other factors may play a role. 
 
Co-stimulation is Required for the Pro-survival Effects of Late Ag. 
Although naïve T cells require co-stimulation for effective stimulation, it was 
unclear if effector CD4 T cells had a similar requirement. To test this, I isolated 6 
dpi OT-II effectors and co-cultured with irradiated Thy1-depleted splenocytes from 
PR8-infected mice in the presence or absence of OVAII. I included conditions with 
OVAII and blocking Ab against CD80, CD86, CD70, 41BBL, OX40, CD40, or 
isotype controls. I found that after 6 days of culture, cell recovery was significantly 
reduced in groups where CD86 was blocked (Figure 3.24A). Blocking CD40 led to 
a consistent decrease in cell recovery across experiments but it did not reach 
statistical significance. Additionally, cell death indicated by 7-AAD staining was 
increased most substantially in the groups where CD86 was blocked, but it was 
also increased in groups where OX40L and CD40 were blocked (Figure 3.24B).  
 To further examine the role of co-stimulation during this late checkpoint, I 
isolated 6 dpi effectors and co-cultured with irradiated splenocytes from PR8-
infected mice in vitro with or without Ag, or with Ag plus CD80 and CD86 blocking  
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Figure 3.23. IL-2 is required for the pro-survival effects of late Ag in 
polyclonal cells.  
 
(A-F) Total CD4 T cells were isolated at 6 dpi and co-cultured with irradiated APC 
with or without NP311 325 peptide as in (Figure 3.18A) including a condition with Ag 
plus aCD25 + aCD122. Cells were stained with CFSE. (A) Representative flow 
cytometry plots of IAb- NP311 325 tetramer staining after 6 days of culture. (B) Cell 
recovery after 6 days of culture. (C) CFSE dilution of NP311 325-specific cells after 
6 days in culture. (D) Percentage of NP311 325-specific cells that were 7-AAD+ after 
6 days of culture. (E) Bim expression of NP311 325-specific cells after 6 days of 
culture. (F) CD127 expression of NP311 325-specific cells after 14 days of culture. 
Data is representative of 2 experiments, n=3 each, mean ± SD.  
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Figure 3.24. CD86 co-stimulation promotes survival during late Ag 
stimulation. 
 
(A, B) 6 dpi OT-II.Thy1.1+/  effectors were isolated and co-cultured with irradiated 
APC with or without OVAII peptide as in (Figure 3.17A), including conditions in 
which OVAII peptide was provided in addition to blocking Ab against CD80, CD86, 
CD70, 41BBL, OX40L, CD40 or isotype controls. Cells were cultured for 6 days. 
(A) Cell recovery is shown. (B) Cell death as measured by 7-AAD staining is 
shown. Data is representative of 2 experiments, n=3 each, mean ± SD.   
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Ab. I chose to block both CD80 and CD86 since both are ligands for CD28 co-
stimulation. Again, after 6 days of culture there was a significant reduction in cell 
recovery when CD28 co-stimulation was blocked (Figure 3.25A). This did not 
appear to be due to proliferation, as cells stimulated with Ag proliferated to a similar 
extent whether or not they received CD28 co-stimulation after 2 days of culture 
(Figure 3.25B). However, when CD28 co-stimulation was blocked, cell death was 
significantly increased as measured by 7-AAD staining (Figure 3.25C). Given that 
CD28 stimulation can promote IL-2 production, I stained for IL-2 after 4 hours of 
culture and found that blocking CD28 co-stimulation did result in a decrease in the 
amount of IL-2 produced (Figure 3.25D). Since blocking CD28 co-stimulation did 
not result in a complete abrogation of IL-2 production, it is likely that it has IL-2 
independent effects on survival. These findings suggest that co-stimulation at this 
late time has minimal if any impact on proliferation of effectors, but has a large 
impact on cell survival following late Ag stimulation.  
 
Ag Recognition at the Effector Phase Promotes the Immediate Expression of 
Molecules Linked to Memory Formation. 
Since Ag/APC exposure of 6 dpi effectors at the effector phase promotes 
the formation of a larger cohort of memory cells, as opposed to driving terminal 
differentiation, I tested if it also promoted expression of known memory-associated 
markers. I transferred OT-II.Nur77GFP.Thy1.1+/  naive cells to hosts, infected with 
PR8-OVAII, and harvested lung, spleen, and DLN at 5,7, and 9 dpi. I analyzed  

	 129	
Figure 3.25. CD86 co-stimulation promotes survival during late Ag 
stimulation and reduces IL-2 production. 
 
(A-D) 6 dpi OT-II.Thy1.1+/  effectors were isolated and co-cultured with irradiated 
APC with or without OVAII peptide as in (Figure 3.17A). A condition was included 
with OVAII peptide and aCD80 and aCD86 blocking Ab. Cells were stained with 
cell trace violet (CTV) (A) Cell recovery after 6 days of culture. (B) Dilution of CTV 
after 2 days of culture. (C) Cell death as measure by 7-AAD staining after 2 days 
of culture. (D) IL-2 production after 4 hours of culture. Data is representative of 3 
experiments, n=3 each, mean ± SD. 
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donor GFP+ cells (recent Ag exposure) vs. GFP  cells (no recent Ag exposure). I 
found that GFP+ cells expressed higher levels of CD25 at 5-7 dpi in the lung 
compared to GFP  cells (Figure 3.26A). The timing of this CD25 expression 
matches when IL-2 signals are required for CD4 memory formation (1). 
Additionally, CD27, a costimulatory molecule thought to be important for memory 
formation (1), was increased in GFP+ cells in the lung at 7 dpi (Figure 3.26B). Other 
effector markers such as PD-1 were not different between GFP+ and GFP  cells in 
the lung at any time point (Figure 3.26C). This confirms that both GFP+ and GFP  
effectors are all fully activated at these time points. Both CD25 and CD27 were 
also upregulated in GFP+ polyclonal NP311 325+ cells in the lung at 7 dpi in Nur77GFP 
mice (Figure 3.26D). Although the CD25 upregulation was no longer apparent in 
OT-II cells by 7 dpi, there was still a difference in NP311 325+ cells. By harvesting at 
7 dpi, I may have missed the peak of CD25 expression in the polyclonal population. 
However, at earlier time points tetramer detection of polyclonal IAV cells in the lung 
is very difficult. Further, I found that following 2 days of culture using the in vivo to 
in vitro system described in Figure 3.17 and Figure 3.18, CD25 expression was 
increased in both OT-II and polyclonal NP311 325+ cells (Figure 3.26E). 
At 7 dpi, both GFP+ OT-II and polyclonal NP311 325+ cells in lung, spleen and 
DLN also expressed higher levels of Bcl-6, a transcription factor implicated in 
memory formation (232, 235) (Figure 3.27A, 3.27C). In contrast, expression of T-
bet, a transcription factor thought to promote terminal differentiation (205, 285, 
286), was equivalently expressed between GFP+ and GFP  cells in both OT-II and  
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Figure 3.26. CD25 and CD27 upregulated in following late Ag encounter in 
the lung. 
 
(A-C) 5x105 naïve OT-II.Nur77GFP were transferred to B6 mice.  Mice were infected 
with PR8-OVAII. Lung cells were harvested at 5, 7, and 9 dpi. GFP+ and GFP  
donor cells were analyzed for CD25 expression (A), CD27 expression (B), and PD-
1 expression (C). (D) Nur77GFP mice were infected with PR8-OVAII. At 7 dpi, GFP+ 
and GFP  NP311 325-specific cells were analyzed for CD25 and CD27 expression in 
the lung. (E) 6 dpi OT-II.Thy1.1+/  effectors or total CD4 T cells were isolated and 
co-cultured with irradiated APC with or without OVAII or NP311 325 peptide 
respectively as in (Figure 3.17A, 3.18A). After 2 days of culture, CD25 expression 
was measured in OT-II (left) and NP311 325-specific cells (right). Data is 
representative of 3-4 experiments, n=3-5 each, mean ± SD. Data is representative 
of 3 experiments, n=3 each, mean ± SD. 
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polyclonal cells (Figure 3.27B, 3.27D). I confirmed the upregulation of Bcl-6 
following short-term late Ag presentation using the in vivo to in vitro model 
described in Figure 3.17 and Figure 3.18. After 2 days of culture, Ag/APC had 
induced both OT-II and NP311+ cells to upregulate Bcl-6 compared to culture with 
APC alone (Figure 3.28A).  
Although, Bcl-6 expression is promoted by phosphorylated STAT3 
(pSTAT3) (316) and IL-2 is not generally thought of as a STAT3 activating 
cytokine, it has been shown to promote phosphorylation of STAT3 (317, 318). I 
therefore tested if blocking IL-2 effected Bcl-6 expression after 2 days of culture. I 
found that blocking IL-2 had no effect on Bcl-6 expression (Figure 3.28B). This 
finding is not surprising given their largely antagonistic nature (227, 235). In 
addition to promoting Bcl-6 expression, pSTAT3 also promotes CD8 memory T cell 
formation (316, 319). I tested if late Ag promoted STAT3 phosphorylation and 
found pSTAT3 was indeed substantially increased following Ag stimulation of 6 dpi 
effectors after 4 hours of culture (Figure 3.28C). IAV-specific CD4 T cells are 
known to produce high levels of IL-10 during the effector stage (4).  
Additionally, IL-10 is known to induce STAT3 phosphorylation (319, 320). 
Therefore, I tested if blocking IL-10 would have an effect on cell survival following 
late Ag. I found that while polyclonal CD4 T cells had reduced cell survival after 6 
days of culture when IL-10 was blocked, OT-II cells did not (Figure 3.28D, 3.28E). 
Since the polyclonal culture contained all CD4 T cells isolated at 6 dpi, while the 
OT-II culture contained only donor OT-II cells, it is likely that the polyclonal  
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Figure 3.27. Bcl-6 is upregulated following late Ag encounter in all organs in 
both OT-II and polyclonal cells. 
 
(A,B) 5x105 naïve OT-II.Nur77GFP were transferred to B6 mice.  Mice were infected 
with PR8-OVAII. Lung, spleen, and DLN were harvsted at 7 dpi. GFP+ and GFP  
donor OT-II cells were analyzed for Bcl-6 (A) and T-bet (B) expression. (C-D) 
Nur77GFP mice were infected with PR8-OVAII. At 7 dpi, GFP+ and GFP  NP311 325-
specific cells were analyzed for Bcl-6 (C) and T-bet (D) expression. Data is 
representative of 3-4 experiments, n=3-5 each, mean ± SD. 
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Figure 3.28. A Stat3 inducing cytokine may play a role in survival following 
late Ag stimulation. 
 
(A-E) 6 dpi OT-II.Thy1.1+/  effectors or total CD4 T cells were isolated and co-
cultured with irradiated APC with or without OVAII or NP311 325 peptide respectively 
as in (Figure 3.17A, 3.18A). (A) Bcl-6 expression was measured in OT-II (left) and 
NP311 325-specific cells (right) after 6 days of culture. (B) Bcl-6 expression was 
measured in NP311 325-specific cells after 2 days of culture without Ag, with Ag, and 
with Ag plus aCD25 and aCD122 blocking Ab. (C) Phosphorylated STAT3 staining 
of OT-II cells after 4 hours of culture. (D, E) Cell recovery of NP311 325-specific (D) 
or OT-II (E) cells after 6 days of culture without Ag, with Ag, and with Ag plus aIL-
10 blocking Ab. Data is representative of 3 experiments, n=3 each, mean ± SD. 
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population included more IL-10 producing cells, possibly including regulatory T 
cells (Treg). Therefore, more work is needed to fully elucidate the role of STAT3 
inducing cytokines on promoting the transition to memory following Ag recognition 
at the effector phase of the CD4 T cell response. These findings demonstrate that 
when Ag is recognized by fully activated effector cells, even in the presence of 
activated APC, the cells do not upregulate molecules associated with further 
terminal differentiation (T-bet or PD-1) but instead upregulate molecules that 
promote the transition to memory. 
To further investigate what genes are upregulated by 6 dpi effectors that re-
encounter Ag, I isolated 6 dpi OT-II effectors and cultured them either in media 
alone or in the presence of plate bound aCD3 and soluble aCD28 for 2 days. I 
then sorted live donor cells and isolated RNA from the group cultured in media 
alone (Media), the group cultured with aCD3 and aCD28 (TCR) and cells isolated 
at 6 dpi (6 dpi effectors) and performed a microarray experiment. I then identified 
genes that were upregulated by 2 fold or more in the TCR group compared to both 
the media group and 6 dpi effectors group. Since, in this case, the media alone 
group is not a true “control” group, I thought it was important to identify the changes 
as compared to the “time 0”, which in this experiment, is the freshly isolated 6 dpi 
effectors. This comparison ensured that the genes I identified were induced 
following late Ag stimulation and did not include genes that remained the same as 
6 dpi effectors but had decreased in the media group.  
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I then sorted genes meeting these criteria into various functional groups as 
defined using The Database for Annotation, Visualization and Integrated Discovery 
(DAVID), a tool provided by the National Institute of Allergy and Infectious 
Diseases (NIAID). To provide perspective on the gene induction following TCR 
stimulation of activated effectors compared to that of naïve cells, I included the fold 
induction seen when naïve T cells are stimulated with aCD3 and aCD28 for 2 days 
in culture, this data was generated by Rabenstein et al. and I obtained it from the 
GEO database (Table 3.1-3.4).  
Table 3.1 includes a list of mostly cytokines, chemokines, and various cell 
surface receptors. Many of these that were induced by 6 dpi effectors were also 
induced by naïve cells following TCR stimulation, including Ccl3, Ccl4, Socs2, Ifng, 
Il2ra, among others. However, there were a few genes uniquely upregulated in 6 
dpi effectors, including Il13, Il10, Il4, and Tnfrsf8. IL-13, although largely thought 
to be a Th2 cytokine, can be produced during Th1 and Th17 driven responses 
(321). In these settings, it was shown to have an anti-inflammatory effect on 
responding T cells (321). As mentioned previously, IL-10 induces STAT3 
phosphorylation and has recently been shown to act late during LCMV infection to 
promote memory CD8 T cell formation (322).  
IL-4 is a Tfh-associated cytokine, its induction following TCR stimulation of 
effectors is consistent with findings that show a skewing in the CD4 T cell response 
to a more Tfh phenotype following persistent Ag (311). Although this study used a 
model of chronic infection, the fact that Tfh express many markers of central 
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memory cells [including Bcl-6, TCF-1, and a greater reliance on oxidative 
phosphorylation (149, 239, 323)] leads to the intriguing possibility that late Ag 
recognition results in a skewing away from the Th1 effector path to a more 
memory-like Tfh path. Tnfrsf8 encodes CD30 which is a co-stimulatory molecule 
that binds a ligand expressed by lymphoid tissue inducer cells which are thought 
to be critical for CD4 T cell memory maintenance (324, 325).  
Many of the transcription factors and signaling molecules were upregulated 
similarly in 6 dpi effectors and naïve CD4 T cells (Table 3.2). However, Nedd4 and 
Pparg were uniquely upregulated in 6 dpi effectors. Nedd4 encodes a E3 ubiquitin 
ligase which has been shown to promote proliferation and IL-2 production in CD4 
T cells (326). Pparg is a fatty acid metabolite driven transcription factor which has 
been shown to suppress effector functions in T cells (327). Rbpj was upregulated 
to a greater extent in 6 dpi effectors than in naïve T cells. Rbpj is a Notch signaling 
protein that has been shown to be required for memory CD4 T cell survival (328). 
Of interest are the transcription factors that are largely upregulated in naïve T cells 
but not upregulated following TCR stimulation of 6 dpi effectors, these include 
Tbx21 (encodes T-bet) and Irf8, two genes implicated in effector differentiation 
(285, 286, 329). Surprisingly, Bcl6 did not reach the 2-fold cutoff. It may be that the 
microarray was not sensitive enough to detect the upregulation of Bcl-6 or that Bcl-
6 protein expression is regulated post-translationally in 6 dpi effectors receiving 
TCR stimulation. 
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6 dpi effectors upregulated a variety of adhesion molecules that were not 
similarly upregulated in naïve T cells (Table 3.3). Additionally, many regulators of 
metabolism were upregulated in 6 dpi effectors and not upregulated in naïve T 
cells (Table 3.4). One of which, Olr1, is upregulated by PPARg and is a receptor 
that mediates increased fatty acid uptake in adipocytes (330). Since memory cells 
transition to fatty acid oxidation as their primary energy source, it is possible that 
increased fatty acid uptake would be advantageous (331). 
Next, I identified genes that were upregulated following culture in media 
compared to the TCR group and 6 dpi effectors group (Table 3.5-3.8). These were 
also separated into functional groups. For consistency, the fold change column in 
these tables still indicates the fold change in TCR/media, therefore values in these 
tables are negative. Table 3.5 includes a list of cell cycle arrest and apoptosis 
genes that are upregulated in the media alone condition. None of these genes 
were similarly upregulated in the media alone condition of naïve cells. This is not 
surprising given that the 6 dpi effector media alone condition is composed of highly 
activated cells that had recently undergone several rounds of proliferation. 
Interestingly, quite a few cell cycle arrest genes were upregulated which is 
consistent with my findings and others that responding CD4 T cells need 
continuous TCR stimulation for continued proliferation (Figure 3.6C, 3.9A) (262). 
Additionally, many metabolism genes were upregulated in the media alone 
condition of 6 dpi effectors that were not similarly upregulated in the media 
condition of naïve T cells (Table 3.6). 
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Tables 3.1-3.4 Genes upregulated in TCR vs. Media and 6 dpi effectors  
 
 
6 dpi OT-II.Thy1.1+/  effectors were isolated as in (Figure 3.17A), and cultured with 
1µg/ml aCD3 and 5µg/ml aCD28 or in media alone for 2 days. Live OT-II.Thy1.1+/  
cells were then sorted and RNA was isolated from the media alone group, the TCR 
stimulated group, and sorted 6 dpi effectors. Microarray analysis was then 
performed on each sample. Genes that were upregulated in the TCR group by 
greater than 2-fold over both the media group and the 6 dpi effector group were 
identified. Genes were then categorized into different functional groups using the 
NIAID DAVID platform. The third column in every table reflects the fold change 
between the TCR group over the media group. The last column of every table 
includes the fold change seen when naïve CD4 T cells are cultured with aCD3 and 
aCD28 or in media alone for 2 days. This data was obtained from GEO database 
deposit of Rabenstein et al. (249). Data is pooled from 2 independent experiments. 
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Table 3.1 Genes upregulated in TCR vs. Media and 6 dpi effectors: 
Cytokines and Chemokines 
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Table 3.2 Genes upregulated in TCR vs. Media and 6 dpi effectors: 
Transcription factors / Signaling 
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Table 3.3 Genes upregulated in TCR vs. Media and 6 dpi effectors: 
Adhesion 
  
Table 3.4 Genes upregulated in TCR vs. Media and 6 dpi effectors:  
Metabolism 
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Many cytokines and cell surface receptors were similarly regulated in the 6 
dpi media condition and the naïve T cell media condition (Table 3.7). However, a 
few genes were uniquely upregulated in the media condition of 6 dpi effectors 
including CD96. CD96 encodes the T cell-activated increased late expression 
protein (Tactile), a protein found to inhibit IFNg production of NK cells (332). Among 
the transcription factors uniquely upregulated in the media condition of 6 dpi 
effectors is Zbtb20 a transcription factor shown to inhibit Foxo1 expression in lung 
cancer cells (333) (Table 3.8). Given the role of Foxo1 in promoting the transition 
to memory in CD8 T cells (334, 335), this may be a mechanism by which these 
cells fail to form memory. While this microarray provides some promising leads 
into which genes may play a role in promoting memory formation following late Ag 
recognition, more work is needed to fully expand upon these potential 
mechanisms. However, it is clear that Ag recognition at the effector stage differs 
from Ag recognition at the naïve stage. Instead of driving terminal differentiation, it 
may promote genes with a slightly suppressive effect, limiting T cell activation and 
driving a memory phenotype. 
 
Memory cells Receiving Short-term Late Ag have an Enhanced Memory 
Phenotype, Function, and Protective ability. 
In the transfer model (Figure 3.5), 6 dpi effector cells transferred to hosts 
without Ag underwent extensive contraction and were often at or below the limit of 
detection within 7 dpt. This low number of memory cells in hosts without Ag  
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Tables 3.5-3.8 Genes upregulated in Media vs. TCR and 6 dpi effectors  
 
6 dpi OT-II.Thy1.1+/  effectors were isolated as in (Figure 3.17A), and cultured with 
1µg/ml aCD3 and 5µg/ml aCD28 or in media alone for 2 days. Live OT-II.Thy1.1+/  
cells were then sorted and RNA was isolated from the media alone group, the TCR 
stimulated group, and sorted 6 dpi effectors. Microarray analysis was then 
performed on each sample. Genes that were upregulated in the media group by 
greater than 2-fold over both the TCR group and the 6 dpi effector group were 
identified. Genes were then categorized into different functional groups using the 
NIAID DAVID platform. The third column in every table reflects the fold change of 
the TCR group over the media group. The last column of every table includes the 
fold change seen when naïve CD4 T cells are cultured with aCD3 and aCD28 or 
in media alone for 2 days. This data was obtained from GEO database deposit of 
Rabenstein et al. (249). Data is pooled from 2 independent experiments. 
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Table 3.5 Genes upregulated in Media vs. TCR and 6 dpi effectors:   
Cell Cycle Arrest / Apoptosis 
Table 3.6 Genes upregulated in Media vs. TCR and 6 dpi effectors:  
Metabolism 
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Table 3.7 Genes upregulated in Media vs. TCR and 6 dpi effectors:   
Cytokines, Chemokines, Surface Receptors 
Table 3.8 Genes upregulated in Media vs. TCR and 6 dpi effectors:  
Transcription / Signaling 
	 150	
hampered my ability to determine the long-term phenotypic and functional 
differences between memory cells generated with or without Ag at the checkpoint. 
To increase the recovery of memory cells that develop without Ag at the 
checkpoint, I cultured in vivo-generated effector CD4 T cells with or without Ag for 
2 days in vitro (as in Figure 3.17), transferred equal numbers of each to uninfected 
mice, and allowed the cells to transition to memory for 7 days (Figure 3.29A). In 
vivo, 3 days without Ag is sufficient for effector CD4 T cells to become virtually 
identical to memory (203). I then assayed cell recovery, phenotype, and cytokine 
production.  
As expected, the donor cells that had been exposed to Ag/APC in vitro, 
formed a significantly larger memory population after transfer to uninfected hosts 
even though their numbers were equivalent at the time of transfer, with 18-fold 
more in lung and 5-fold more in spleen (Figure 3.29B). This indicates that the 2 
days of exposure to Ag was sufficient to confer significantly greater survival. 
Compared to APC without Ag, the donor effector cells exposed to Ag/APC in vitro, 
expressed increased levels of CD127 and CXCR3, a memory marker needed for 
homing and protective function (216, 226) (Figure 3.29C). Moreover, they secreted 
more IFNg and had a higher frequency of IFNg/TNFa double producers after re-
stimulation (Figure 3.29D, 3.29E). These results indicate that even short-term Ag 
recognition at 6 dpi results in both a much larger, and a functionally superior 
memory population.  
  

	 152	
Figure 3.29. Short-term late Ag promotes enhanced memory phenotype and 
function. 
 
(A-E) 6 dpt OT-II in vivo-generated effectors and PR8-activated APC were co-
cultured ex vivo as described in (Figure 3.17A). After 2 days of culture, live cells 
were isolated using Lympholyte and 2x106 cells were transferred to uninfected B6 
mice. (A) Experimental schematic. (B) Cell recovery was determined 7 dpt in the 
lung and the spleen of host mice. (C) CD127 and CXCR3 expression was assayed 
in the spleen at 7 dpt. (D) Representative flow cytometry plots of intracellular 
cytokine staining of cells harvested from the spleen 7 dpt and re-stimulated for 4 
hours with PMA + Ionomycin. (E) Percentage of IFNg+ and IFNg+TNFa+ donor cells. 
Representative data, n=3-4 each, 3 experiments, mean ± SD. 
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To evaluate if the differences in memory formation with or without Ag at the 
checkpoint would lead to differences in protection against a lethal challenge of IAV, 
I transferred 6 dpi OT-II effectors into uninfected B6 mice along with OVAII-pulsed 
or un-pulsed APC. To account for a potential host naïve CD4 T cell response, I 
included a group of mice that received OVAII-pulsed APC without transfer of 6 dpi 
effectors. I also included a group that received naïve OT-II cells to control for the 
possibility that a similar number of naïve donor OT-II could provide enhanced 
protection. Hosts were rested for 2-3 weeks to ensure memory generation, and 
then challenged with a lethal dose of PR8-OVAII (Figure 3.30A). 
Despite the fact that the only memory cells in the hosts were the donor 6 
dpi effectors, the hosts that received effectors plus APC-OVAII were mostly 
protected against lethal infection (12/15), whereas those that received naïve OT-
II, OT-II 6 dpi effectors without Ag, or APC-OVAII alone were largely unprotected 
(Figure 3.30B, 3.30C). Thus, providing effectors with only short-term in vivo Ag 
stimulation at the checkpoint drove the formation of protective memory cells. Since 
the hosts were not previously infected, I conclude that short-term Ag stimulation 
by activated APC, without any viral infection, is sufficient to promote the transition 
of 6 dpi effectors to become protective memory. 
 
Late Ag Enhances Memory Formation in a Cold-adapted Vaccination Model. 
My findings establish a checkpoint that occurs at 6-8 dpi following IAV 
infection where Ag recognition drives functional memory CD4 T cell formation.  
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Figure 3.30. Short-term late Ag is required for the formation of a protective 
memory CD4 T cell response. 
 
(A-C) 6 dpi OT-II effector cells were generated in vivo as described in (Figure 3.5A) 
and transferred to uninfected mice along with either OVAII-pulsed APC (APC-
OVAII) or unpulsed APC. One group of mice received OVAII-pulsed APC alone (no 
effectors). Another group received 5x105 naïve OT-II cells. After 2-3 weeks, hosts 
were challenged with 2LD50 PR8-OVAII. (A) Experimental schematic. (B) Weight 
loss curves. (C) The survival of mice was plotted. Pooled data, n=14-15, 3 
experiments. Significance for Figure 3.30C was determined using the Log-rank 
(Mantel-Cox) test. 
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Since many standard vaccinations likely do not induce the persistent levels of Ag 
that live virus does, I postulate that memory CD4 T cell formation following 
vaccination is normally constrained by a lack of Ag at the checkpoint. Therefore, 
the addition of Ag/APC at this time may enhance vaccine-induced memory. To test 
this premise, I immunized with a live attenuated, cold-adapted (ca) influenza 
vaccine (ca.IAV). Replication of ca.IAV is limited to the upper respiratory tract, 
potentially limiting the duration of Ag presentation. The ca.IAV vaccine LAIV has 
been shown to induce enhanced T cell responses when compared to inactivated 
vaccines suggesting that it had the greatest potential for persisting Ag (18). To 
determine if Ag persisted into the effector phase following ca.IAV inoculation, I 
immunized Nur77GFP mice with ca.A/Alaska/6/77CR29 (ca.Alaska) and measured 
GFP expression in immunization-induced effector T cells. Previous work in our lab 
showed that ca.Alaska induces a strong heterosubtypic response to PR8 and that 
the NP311 325 is a dominant CD4 epitope shared between these two viruses (83). At 
7 dpi, effector NP311 325-specific cells expressed no GFP after ca.Alaska 
immunization indicating no recent Ag recognition (Figure 3.31), while in mice 
infected with PR8, or a non-ca H3N2 strain (A/Philippines/2/82/x-79), a cohort of 
NP311 325+ cells were GFP+, indicating recent Ag recognition in the live infections. 
 To determine if the addition of Ag during the checkpoint could boost memory 
following ca.Alaska immunization, I added NP311 325-pulsed APC at 6 dpi to 
ca.Alaska-immunized mice and assayed memory CD4 T cell formation by 
enumerating NP311 325 tetramer positive cells after 33-44 dpi (Figure 3.32A). I found  
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Figure 3.31. Cold-adapted virus fails to present Ag during the effector phase 
of the response. 
 
Nur77GFP expression of CD4+CD44h  NP311 325 tetramer+ cells or CD4+CD44 o naïve 
cells in the lung on day 7 following PR8 (H1N1) infection, Philippines (H3N2) 
infection, or ca.Alaska (H3N2) immunization. Representative data, 2-3 
experiments, n=3-4 mean ± SD. 
  
	 159	
significantly more NP311 325+ CD4 T cells in the lung and spleen, although there was 
no difference in the number of donors found in the DLN (Figure 3.32B). This finding 
suggests that the memory checkpoint exists for effectors generated by attenuated 
as well as live WT influenza infection. Additionally, it shows that the introduction of 
Ag/APC at the checkpoint can promote effector CD4 T cells induced by attenuated 
virus immunization to form more memory without the need for persisting live virus. 
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Figure 3.32. Memory CD4 T cell formation is enhanced following cold-
adapted IAV vaccination with the addition of short-term Ag at 6 dpi.  
 
(A, B) B6 mice were immunized with 2500 TCID50 ca.Alaska intranasally. 6 days 
later, 2x106 NP311 325-pulsed APC were added via intravenous injection. (A) 
Experimental schematic. (B) Quantification of NP311 325 tetramer+ memory 
CD4+CD44h  T cells in the lung, spleen, and DLN 33-44 days following 
immunization. Representative FACS plots shown, 2-4 independent experiments. 
Pooled cell recovery data, 3 independent experiments, n=4-5 each, mean ± SD. 
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CHAPTER IV: DISCUSSION 
 
 
Overview 
 
The mechanisms that govern the selection of memory cells from the effector 
population remain unclear. Some have proposed that the initial interaction with 
cognate Ag during priming programs cells toward either effector or memory 
differentiation (283, 284, 288–290). While these models certainly inform the 
heterogeneity seen at the effector stage of the T cell response, they do not exclude 
the possibility that events occurring at later stages may influence memory T cell 
formation.  
Studies from our laboratory and others suggest that signals occurring at the 
effector stage can enhance memory T cell formation (1, 138, 139, 211). McKinstry 
et al. demonstrated that CD4 T cells required autocrine IL-2 signals between 5-7 
dpi to form memory (1). Given that Ag recognition is a main driver of IL-2 production 
in CD4 T cells, the aim of my thesis project was to determine if Ag at this time point 
was also required for memory formation. While much work has been done 
examining the role of Ag in memory CD4 T cell formation, virtually all studies have 
focused on the priming phase of the response (260, 305). This was likely a result 
of the pervasive concept of AICD (151, 159, 160) and a few findings that 
demonstrated that prolonged Ag presentation can be deleterious to memory 
formation (246, 263).     
This thesis work demonstrates that CD4 T cells require Ag recognition 
during the effector phase of the response to continue undergoing proliferation and 
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to form a functional and protective memory population. These findings suggest that 
CD4 memory T cell population size and function is not predetermined at the 
priming stage. In fact, it requires additional signals including TCR stimulation, IL-2 
signaling, and co-stimulation during the effector phase immediately preceding the 
onset of contraction. I found that, at this time, these signals promoted a 
transcriptional program of memory-associated genes including CD25 and Bcl-6. 
The long-term effects of Ag recognition at this time point included upregulation of 
the memory markers CD127 and CXCR3, as well as the formation of more multiple 
cytokine producing and protective memory CD4 T cells (Figure 4.1). Further, I 
found that short-term Ag stimulation without systemic inflammatory cytokines at 
this late time point were sufficient to fulfill the requirements of memory formation 
which may have important implications for vaccine design. 
 
Ag Recognition during the Course of an Immune Response. 
The finding that Ag recognition during the course of the effector response 
was limited provides great insight into how Ag may shape the ongoing immune 
response. The Nur77GFP experiments clearly demonstrate that at 3 dpi virtually all 
the cells in the DLN and spleen had recently encountered Ag and were therefore 
GFP+ following isolation (Figure 3.2B). Just 2 days later, the vast majority of T cells 
in the SLO were GFP  indicating that they likely did not receive additional TCR 
stimulation after that initial signal at 3 dpi. These GFP  cells were all CD44h  
indicating that they were not “late comers” and were sufficiently primed. In  
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Figure 4.1. Late Ag Checkpoint model for memory formation. 
 
Model summarizing the central findings presented in this thesis. I find that 
responding CD4 T cells require Ag, IL-2, and co-stimulation during the effector 
stage of the response to become memory. Late Ag increases Bcl-6, CD25, and 
phosphorylated STAT3, and decreases Bim expression. Memory cells generated 
with late Ag recognition have increased CD127 and CXCR3 expression, increased 
multiple cytokine producing ability, and protective function. 
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fact, studies have demonstrated that the recruitment of Ag-specific cells during 
priming is quite efficient (336). This pattern of GFP expression is consistent with 
the model of priming in which T cells engage in prolonged contact with Ag/APC, 
followed by a phase of Ag-independent proliferation (245, 266–268). However, 
studies suggest that CD4 T cells were capable of and even required additional Ag 
contacts during this phase of proliferation (269, 272). Given that some cells do 
express GFP at 5 dpi, these additional contacts are likely to occur but they do not 
appear to be the norm. A caveat of these early time points is that since polyclonal 
cells are present a such low numbers early during infection, I was unable to confirm 
a similar pattern of GFP expression in endogenous cells at this time. However, the 
microscopy studies detailing the phases of T cell priming, including the studies 
demonstrating a CD4 T cell requirement for additional contacts were also 
conducted with transgenic T cells (266–269, 337).  
Another interesting finding of the Nur77GFP studies was that many of the 
responding CD4 T cells in the lung of infected mice do not re-encounter Ag 
between 5-9 dpi. This is despite the continued presence of Ag at these time points 
(306). Additionally, there is still a significant amount of virus present in the lung 
between 5-9 dpi (Figure 1.2). These findings are in agreement with a two-photon 
microscopy study in which in vitro-generated rested effectors were transferred into 
PR8-OVAII-infected mice at 7 dpi and 24 hours later, around 35% of transferred 
cells were arrested indicating Ag recognition (307). It is likely that the immune 
system generates a CD4 T cell response far bigger than what is needed and since 
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CD4 T cell cytokine production appears to be focused around sites of significant 
Ag burden (307), the immunopathology costs of doing so are limited.   
Additionally, the phenomenon of CD4 T cells not recognizing Ag despite its 
presence has been observed with microscopy studies. These studies found that 
PD-1 interactions promoted T cell mobility which may limit their ability to receive 
strong TCR signals (338, 339). Effector CD4 T cells in the lung express high levels 
of PD-1, so this may be a relevant mechanism by which effectors receive limited 
TCR signals. Others have found that activated CD4 T cells undergo a programmed 
downregulation of TCR beginning at the peak of the T cell response (340) which 
may explain why there is so little Ag recognition between 9-14 dpi. This may be a 
mechanism to limit immunopathology and shut down the response even in the 
presence of continuing Ag presentation (306). 
The Nur77GFP kinetics experiment in Figure 3.2 also demonstrates that a 
few responding CD4 T cells still recognize Ag at 14 dpi. Despite this, 14 dpi 
effectors do not proliferate either following transfer (Figure 3.6C) or in situ (140). 
In Brdu labelling studies, Roman et al. demonstrated that proliferation in CD4 T 
cells during IAV infection ceases around 12 dpi (findings I have confirmed in my 
experiments) especially in the SLO which is where the most Ag recognition is 
occurring at this time (Figure 3.2). It may be interesting to determine the context of 
this Ag presentation, if it is occurring in germinal centers it may be that T follicular 
regulatory cells inhibit proliferation of these cells (341, 342).  Microscopy studies 
identifying where effectors cells localize late in the response compared to 
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transferred naïve cells might be informative in discovering any potential niche or 
migration-dependent regulation of Ag recognition of responding T cells during 
contraction. 
 
Short-term Ag Requirement. 
 Previous work from our lab has demonstrated that responding CD4 T cells 
require IL-2 signals between 5-7 dpi to form memory. Similarly, the transfer 
experiments using short-term Ag/APC at 6 dpi have demonstrated that Ag 
presentation during this limited window is sufficient for optimal memory formation 
(Figure 3.11, 3.12, and 3.14). Additionally, if 6 dpi effectors do not receive TCR 
signals at this time they undergo a sharp contraction (Figure 3.5E) and the memory 
cells that do form have limited functional ability (Figure 3.29D, 3.29E). Ag 
recognition at the effector phase appears to be critical for many aspects of memory 
T cell formation. It downregulates Bim expression promoting cell survival (Figure 
3.21). It induces CD25 expression which enhances the ability of cells to receive IL-
2 signals (Figure 3.26). It induces memory-associated molecules CD27 (Figure 
3.26B) and Bcl-6 (Figure 3.27A, 3.27C) which may play a critical role in the 
necessary metabolic switch for a successful transition to memory (235). It 
programs the gradual upregulation of memory markers CD127 and CXCR3 (Figure 
3.20B, 3.20D, 3.29C). Finally, it programs their ability to become memory with 
multi-cytokine producing potential (Figure 3.29D, 3.29E). Therefore, 6-8 dpi is 
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certainly a critical time in the formation of the heterogeneous, multi-functional 
memory population that is formed following influenza infection. 
 Future work may address whether or not this time point is similarly important 
during other viral infections. It is likely that acute infections that exhibit a similar T 
cell kinetics may be governed by the same principles as influenza infection. 
Alternatively, different inflammatory environments present during priming may alter 
how effectors interpret subsequent Ag encounter. The findings in this thesis 
demonstrate that PR8 infection generates CD4 effectors that are highly activated 
and will undergo apoptosis if they do not receive Ag stimulation at the effector 
phase. It may be that priming conditions that do not drive such extensive 
differentiation may not generate effectors that have such a requirement. However, 
the fact that effectors generated with cold-adapted virus also formed an enhanced 
memory population with the addition of Ag at 6 dpi suggests that this phenomenon 
is not restricted to the highly differentiated effectors generated by live viral 
infection. However, the results seen in the cold-adapted model were not as 
impressive as those seen with effectors generated by live viral infection, 
suggesting that either these cells were less dependent on the late Ag checkpoint 
or the administration of Ag was not as efficient at reaching effector cells as it is in 
the transfer models. Given that the numbers of memory cells generated was fairly 
low in the cold-adapted model (Figure 3.32B), it is likely that the Ag/APC were not 
able to reach enough NP311 325-specific effector cells to generate a robust memory 
population.  
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 This thesis does not examine at what point Ag recognition becomes 
deleterious. CD4 T cells are critical for controlling chronic viral infections (343, 344) 
and studies suggest that CD4 T cell exhaustion is quite different from CD8 T cell 
exhaustion including both the loss and gain of effector function (345). During 
chronic viral infection, CD4 T cells appear to skew away from a Th1 phenotype to 
a Tfh phenotype (311, 346). However, in a mouse model with induced Ag 
presentation on DC, continuous Ag stimulation for 10 days resulted in permanent 
loss of IL-2 and TNFa production (300). Interestingly, in this study survival was not 
affected by continuous Ag signaling again contradicting a potential role for AICD 
in regulating the contraction of CD4 T cells (300). It is therefore unclear to what 
extent prolonged TCR stimulation drives CD4 T cell dysfunction. 
 There is a precedent for late Ag having opposing effects at different times 
during an immune response. A CD8 T cell study found that following immunization 
with peptide and adjuvant, addition of Ag at 4 dpi prevented apoptosis, whereas 
addition of Ag at 7 dpi increased apoptosis. In this study, the peak of the response 
occurred at 5 dpi (3-4 days earlier than in the IAV model) (177) (Figure 1.2). 
Therefore, it is possible that Ag recognition during the contraction phase may have 
a negative impact on responding T cells. Whether or not this is the case would 
depend on several factors. For instance, if the Ag stimulation is continuous or 
includes intermittent breaks, if the Ag is provided exogenously or from an 
endogenous persisting source, if the Ag is administered in the context of 
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inflammatory cytokines or not are all likely to play a role on how long Ag is 
beneficial to responding T cells.  
 Another question is where is this critical Ag recognition occurring. As the 
Nur77GFP studies demonstrate, a substantial number of GFP+ cells are present at 
this time in both the lung and the SLO (Figure 3.2E). However, since the GFP 
signal lasts for about 24 hours, it cannot be ruled out that cells see Ag in one 
location and quickly migrate to another. Ballesteros-Tato et al. found that CD11bh  
DC peak around 5-7 dpi in the DLN, they suggest the DLN is the dominant site for 
late Ag recognition (137). On the other hand, microscopy studies have shown CD4 
T cell migration arrest around sites of high Ag density in the lungs of PR8-infected 
mice (307). It is likely that Ag recognition occurs in both the lung and the SLO 
during the effector phase of the response and each contribute to the memory 
population as a whole. An intriguing hypothesis is that Ag recognition in the SLO 
promotes a central memory or Tfh-like memory population, while Ag recognition in 
the lung promotes Trm and Th1-like memory. 
 
Memory cell Selection 
A requirement of Ag recognition at the effector stage to generate CD4 T cell 
memory makes teleological sense. First, it would ensure that a substantial memory 
population is only formed when Ag, indicating a continuing threat, persists. If the 
pathogen were rapidly cleared, the generation of T cell memory would be a waste 
of resources. Second, a late Ag-dependent checkpoint may serve to select T cells 
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with high affinity to epitopes that continue to be presented late in the response. 
Studies have shown that memory CD4 T cells have greater functional avidity than 
do the CD4 effectors present at the peak of the response (304), suggesting that 
the cells that become memory include effector cells with the highest TCR avidity. 
Finally, the additional round of Ag-dependent selection may help select a memory 
pool with greater multi-functionality. Many recent studies have demonstrated that 
memory CD4 T cells retain a significant level of the differentiation acquired during 
the effector phase (146, 148, 149, 209). An intriguing hypothesis is that, via the 
memory checkpoint described here, this late Ag interaction may be responsible for 
the selection and formation of more specialized subsets of effectors that become 
memory cells particularly tailored to combat the given pathogen upon re-
encounter. 
The memory cell population only consists of only about ~10% of the effector 
cell population. Therefore, any model proposing a mechanism for selecting 
memory cells must describe how that model could account for such a narrow 
selection of cells to become memory. I believe the proposed model provides a 
mechanism for the selection of a limited number of effector cells to become 
memory (Figure 4.2). First, the Nur77GFP studies demonstrated that Ag recognition 
by effectors is limited (Figure 3.2). Second, experiments presented in this thesis 
(Figure 3.22, 3.23) as well as in a previous publication (1), demonstrate that 
autocrine IL-2 signals are required for the pro-survival effects of late Ag and the 
upregulation of CD127. Given that as effector cells differentiate they can lose the 
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ability to produce IL-2 (4, 347), this may only allow a percentage of the cells that 
re-encounter Ag to go on to form memory. The role of T cell intrinsic factors like 
this are where some of the influences of priming may come into play. While the 
ability to make IL-2 is likely one limiting factor, there may be others that would 
prohibit cells that have undergone extensive differentiation from receiving the pro-
survival, memory programming benefit of late Ag recognition. Finally, the 
requirement for co-stimulation, CD28 in the current work (Figure 3.24, 3.25) and 
CD27 found in our previous study (1), suggests that in order for late Ag recognition 
to promote memory formation it likely must be presented by a professional 
activated APC. Since lung epithelial cells upregulate MHC-II following IAV infection 
(14), it is unclear whether or not all Ag recognition is presented by a professional, 
activated APC. Therefore, it is feasible that via the mechanism described here, late 
Ag recognition could act to select high affinity clones against dominant pathogen 
epitopes that have retained their functional capacity (Figure 4.2).  
 
Memory-associated Genes 
 The experiments in this thesis demonstrate that Ag recognition at the 
memory checkpoint initiates a program of memory-associated changes that results 
in a larger, long-lived memory population with increased CD127 and CXCR3 
expression as well as increased cytokine production. Our Nur77GFP experiments 
highlight that the early signaling events that occur following Ag recognition at the 
checkpoint include an upregulation of CD25, Bcl-6, and pSTAT3. CD25 expression  
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Figure 4.2. Model for selective memory formation of CD4 effector T cells. 
 
This model describes how a late Ag checkpoint may result in the selection of only 
a few effector CD4 T cells to become memory. First, only a small percentage of 
cells will re-encounter Ag at the effector stage. Second, of those that recognize 
Ag, some may be extensively differentiated and therefore unable to produce IL-2, 
or otherwise unable to respond positively to Ag. Finally, out of the cells that 
recognize Ag, and are not terminally differentiated, only a limited number may have 
received co-stimulation in addition to TCR stimulation. This model provides at least 
three levels of selection, and therefore may severely limit the number of effector 
cells that can become memory.  
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is generally heterogeneous at the effector time point and one recent study found 
that CD25h  effector T cells present late in the response preferentially form memory 
(210). Increased expression of the IL-2 receptor late in the response may ensure 
the cells that encountered late Ag would effectively use the autocrine IL-2 required 
for memory formation (1). Bcl-6 was recently shown to promote the metabolic 
switch required for memory formation (235). Ag at the memory checkpoint may 
therefore serve to selectively upregulate Bcl-6 late in the response as cells 
destined to become memory must transition to a self-renewing, resting population. 
The regulatory effect of Bcl-6 in Th1 cells has been shown to reflect the relative 
levels of Bcl-6 and T-bet (230). Since no significant increase in T-bet occurred 
following late Ag stimulation, even a modest increase in Bcl-6 expression may tip 
the balance in favor of a Bcl-6 mediated gene expression program. The main 
known promoter of Bcl-6 expression is pSTAT3, which was also induced following 
late Ag recognition. Future work will determine whether TCR stimulation alone 
promotes Bcl-6 transcription or if a STAT3-inducing cytokine either produced by 
the responding T cell or the APC is responsible for increased Bcl-6 expression.   
 Another interesting avenue of study will be to fully elucidate the differences 
in downstream signaling in naïve versus effector T cells following Ag stimulation. I 
chose to assay changes in gene expression after 2 days of culture for several 
reasons. First, an extensive amount of cell death occurs in the first 2 days of culture 
without Ag (Figure 3.17B). I reasoned that eliminating many cells that were close 
to death from analysis might provide insight into the transcription factors and 
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cytokines responsible for the phenotypic and functional differences seen between 
memory populations formed with or without late Ag. Second, I did not want to 
perform the microarray too long after TCR stimulation because I wanted to catch 
early mediators that initiate memory formation. However, I believe that a 
microarray conducted 12-24 hours after stimulation might be very informative in 
highlighting the differences between effector and naïve TCR stimulation. 
 With the caveat that it certainly does not provide the complete picture, the 
microarray analysis presented in this thesis does identify some differentially 
regulated genes that could be promising targets for further study. A couple of 
cytokines that were uniquely upregulated in 6 dpi effectors receiving Ag stimulation 
included IL-10 and IL-13, both encoding cytokines that can have anti-inflammatory 
functions (321, 348). Inhibitory cytokines at this late effector stage may prevent 
terminal differentiation and aid in the transition to a resting state required for 
memory formation. Also, IL-10 may promote STAT3 phosphorylation and aid in 
memory formation as it has been shown to do in CD8 T cells (322). Although, I 
didn’t see an effect when blocking IL-10 in the OT-II cell culture (Figure 3.28E), 
there was a significant effect in the polyclonal cell culture (Figure 3.28D). The 
microarray data suggest that OT-II cells are capable of producing IL-10 (Table 3.1) 
so more work is needed to determine if they in fact secrete IL-10 and if it promotes 
memory formation of CD4 T cells. Additionally, the TNF receptor family member 
CD30 was upregulated specifically in effector T cells following Ag stimulation. The 
ligand for this receptor CD30L is expressed by lymphoid tissue inducer cells which 
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have been shown to be essential for CD4 memory T cell maintenance (324, 325). 
The literature on this receptor is not extensive so further work is needed to 
determine if it potentially plays a role in CD4 memory T cell formation during 
influenza infection. 
 
Potential Implications for Vaccine Design 
It is well established that live infections (and vaccines mimicking them) 
generate the best immunity (small pox and others) while newer vaccines 
containing purified proteins with little or no adjuvant induce weak T cell immunity 
(18, 293). My results suggest that one key reason such vaccines may generate 
poor memory is because they do not induce sufficient Ag presentation at the 
effector stage. I tested this using ca.IAV because it is an attenuated virus that is 
capable of replication in the cooler upper respiratory tract making it the best 
vaccine candidate for prolonged Ag presentation. However, by 7 dpi with ca.IAV, 
there was no evidence of Ag presentation and when I introduced Ag/APC 6 days 
after ca.IAV vaccination it significantly improved memory CD4 T cell generation. 
This suggests that strategies to provide Ag/APC at a relevant checkpoint for each 
vaccine may often enhance memory CD4 T cell formation. Indeed in another 
scenario, an early “boost” strategy efficiently promoted CD8 T cell memory (302). 
Importantly since I find no need for live virus at the checkpoint, it is possible that 
an optimal vaccine response could be achieved without the destructive 
inflammatory milieu generated by replicating live virus or systemic adjuvants. 
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Although the exact timing and optimum approach for providing Ag at the 
checkpoint may need to be tailored to the specific vaccine, I anticipate such an 
approach could be developed to improve vaccines in humans (301) (Figure 4.3). 
A potential “early boost” model for vaccination would include the use of 
either an infectious agent or protein with pattern recognition receptor agonists as 
the primary immunization. Infectious agents such as LAIV or MVA are most likely 
to provide pattern recognition receptor ligands to ensure full activation of APC 
required for the generation of adequate T cell responses (53, 301). The secondary 
boost could be attained either by targeting Ag to DC populations (349) or providing 
a large bolus of recombinant Ag with adjuvant to ensure activation of APC (Figure 
4.3). Future work in our lab is seeking to determine the efficacy of these vaccination 
strategies. 
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Figure 4.3. Model for a Two-Step Vaccine Approach. 
 
Model outlining a potential two-step vaccine approach. Step one would ideally 
include immunization with an infectious, attenuated agent that sufficiently activates 
APC and leads to substantial T cell activation. Step two would include a second 
immunization about 5-7 days later, specific timing would have to be empirically 
tested.  
 
Figure adapted from: Devarajan, P., B. Bautista, A. M. Vong, K. K. McKinstry, T. 
M. Strutt, and S. L. Swain. 2016. New Insights into the Generation of CD4 Memory 
May Shape Future Vaccine Strategies for Influenza. Front. Immunol. 7: 136. 
Creative Commons Attribution license. 
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